

Prof. Dr. Maitham Ghaly Yousif, Ph.D., University of Al-Qadisiyah College of Science, Department of Biology
Prof. Fadhil G. Al-Amrani, M.D., Kufa University, College of Medicine
Prof. Nasser G. Yousif, M.D., AlMuthanna University, College of Medicine
Prof. Dr. Alaa M. Sadeq, M.D., Kufa University, College of Medicine
Assist. Prof. Dr. Risala H. Allami, Ph.D., Al-Nahrain University, College of Biotechnology
Assist. Prof. Bahaa A. Razzaq, M.D., Kufa University, College of Medicine
Prof. Dr. Subhi J. Hamza, Ph.D., Al-Nahrain University, College of Biotechnology
Assist. Prof. Ghaidaa J. Mohammed, Ph.D., University of Al-Qadisiyah College of Science Department of Biology
Dr. Diyar K. Flaifel, Ph.D., University of Al-Qadisiyah College of Science Department of Biology
Lecturer Dhuha M. Jabir, M. Sc, University of Al-Qadisiyah/College of Science Department of Biology
Prof. Najah R. Hadi, M.D., Ph.D., Kufa University, College of Medicine
Prof. Natalia G. Daruech, M.D, Cellular Ecology Lab. Departamento Ecología, FCCBB, Pontificia Universidad Católica de Chile
Dr. Samar M. Al-fadhel, Ph.D., National University for Science and Technology
Prof. Douglas Hainz, M.D., Ph.D., American Society of BioMedicin

Revised by

Prof. Nasser Ghaly Yousif
Al Muthanna University, College of Medicine, Iraq
Prof. Lawrence Nofer
Department of Immunology, Medical University of Bialystok, Poland
Prof. Christopher Schultz
Department of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, Canada
Prof. Justin Sambol
Laboratory of Experimental Cardiology, University Medical Center Utrecht, Netherlands

Scholars
LITERATURE

ABOUT US

Scholars Literature is an international open-access journal publisher with a vision to provide quality editorial services to academic researchers, industrial professionals and committed to disseminate top-notch scholarly research and latest information in diverse fields of Science, Technology, and Medicine.

Scholars Literature was founded in the year 2019 with 6 scholarly journals. We aim to publish high-quality research and the latest breakthroughs that can be easily accessed online by everyone without any financial barriers through our journals. Our peer-reviewed scholarly journals have an ever-increasing readership of millions of researchers worldwide.

Currently, Scholars Literature publishes 10 journals in electronic format. Our journals cover various disciplines in pharmaceutical research and development, medical subspecialties, technology, and social sciences. We are making every effort to index our journal articles in reputable databases like PubMed, Scopus, Medline, SCI, DOAJ etc. We strive to reach top among the list of high impact factor journals that are available worldwide.

We are committed to provide the best possible service to our journal authors, reviewers, and editors. Below, are the few services offering to our authors:

- Online manuscript submission and tracking
- Thorough double-blinded peer-review
- Responsive editorial and publishing support
- Extensive global readership and online visibility
- Professional designs, high-quality printing, options for print-on-demand
- Wide dissemination through social networks, press releases, and dedicated PR campaigns.

About Books

Scholars Literature is happy to build on valued partnerships with authors to bring quality books to the professionals and institutions throughout the world.

We work with a dedicated team of professionals to create content that is optimized for delivery in a variety of electronic formats, including potential publication, which is widely reached worldwide. Scholars Literature helps you, save time and create content that's available to anyone, anywhere and anytime they need it most.

The books are properly peer-reviewed, edited and proof read before bringing them online. Scholars Literature offers an end-to-end content creation platform. Once that content is created, our marketing and sales team will take care of promoting your work .

Content Type

Scholars Literature offers a range of digital and print products to suit different subject areas, information types and customer/author needs. These include: reference, textbooks, fast-turn content, Major Reference Works, laboratory and practical manuals.

Although this is not an exhaustive list, the following are the broad subject areas in which we are looking for content

- Biomedical Research
- Chemistry
- Food Sciences
- Clinical Education
- Continuing Medical / Health Education
- Health Sciences
- Data and Analytics
- Earth Science
- Energy
- Engineering
- Environmental Science
- Food Science and Nutrition
- Life Sciences
- Materials Science
- Medical Education
- Medicine
- Neuroscience
- Nursing
- Nursing Education
- Psychiatry
- Psychology
- Surgery
- Sustainability Science

Copyright

Preface

COVID-19 is the infectious disease caused by the most recently discovered coronavirus. This new virus and disease were unknown before the outbreak began in Wuhan, China, in December 2019. COVID-19 is now a pandemic affecting many countries globally, such a situation has not existed since the flu pandemic in 1918.

In this book we aimed togive guidance on the full range of significant health issues associated with this threatening disease which is often severe and fatal with no proven treatment and vaccines to day of published this book.

The book comprises seven chapters, the first chapter provides a general introduction on the history of the COVID-19. Subsequent three chapters cover the basic aspects of virology including the epidemiology, molecular changes of SARS-CoV-2 genome, and immunological aspects regarding COVID-19. The five chapters that follow diagnosis ofCOVID-19, while six and seven chapters exploring developments and recent researches in the field treatment and vaccine of COVID-19.

This book is the product of a collaboration effort. We wish to express our appreciation to all the contributing authors. We are especially grateful to members of the revising team, Prof. Lawrence Nofer, Prof. Christopher Schultz and Prof. Justin Sambol for providing support, feedback, and guidance during the process. Gratitude is extended to many of our colleagues for their advice and helpful discussions. Finally, we believe a clear head is crucial in times of over information, with dozens of scientific papers published every day regarding COVID-19, news about hundreds of studies being planned or already on the way and social media blending hard data with rumors and fake news.

11th June 2020

Prof. Nasser GhalyYousif

Contents

Chapter One Introduction to COVID-19	12-24
Chapter Two Epidemiology of COVID-19	29-34
Chapter Three Molecular Changes of SARS-CoV-2 Genome and Emergent of New Variants	39-49
Chapter Four Immunological Aspects Regarding COVID-19	54-67
Chapter Five Diagnosis of COVID-19	72-76
Chapter Six Treatment and Prevention	81-97
Chapter Seven Vaccines	102-106

Chapter -1

Introduction to COVID-19

History

At the end of 2019, an increasing number of patients with pneumonia from unknown causes in Wuhan(Hubei, China), with a population of 11 million, has caused concern from the local hospital. On December 29, 4 cases were linked to the Huanan seafood market (The 2019-nCoV Outbreak), in which non-aquatic live animals were also sold, including several species of wild animals. The local Center for Disease Control (CDC) discovered additional patients associated with the same market after the investigation and reported to the China CDC on December 30, 2019.

On the second day, the World Health Organization was informed of the unknown causes of cases of pneumonia by China CDC[1]. During the first outbreak in Wuhan, the virus was usually referred to as "coronavirus" or "Wuhan coronavirus" [2-6] or "Wuhan virus" [7-9]. A few weeks later, In January 2020, WHO recommended "novel coronaviruses-2019" (not -2019) [10] as the temporary name for the virus. This was according to the WHO guidelines for 2015 [11] against the use of geographical locations (such as Wuhan), animal species, or groups of people in the names of diseases and viruses [12,13].

On February 11, 2020, the International Virus Classification Committee adopted the official name "SARS-CoV-2" severe acute respiratory syndrome Coronavirus-2. To avoid confusion with SARS, the World Health Organization sometimes refers to SARS-CoV-2 as the "COVID-19 virus" in public health communications [14,15]. In March 2020, US President Donald Trump referred to the virus as "the Chinese virus" in tweets, interviews, and press briefings for the White House [16,17]. Trump stopped using the term by March 23, 2020, noting social stigma issues [18,19], and from March 11, 2020 when the number of the infections among the countries interested was 114, with more than 118,000 cases and more than 4,000 deaths, the World Health Organization has announced a pandemic [1].

Coronaviruses

Coronaviruses (CoVs) are important pathogens for humans and vertebrates. They can infect the respiratory, gastrointestinal, hepatic, and central nervous system of human, livestock, birds, bat, mouse, and many other wild animals[20-22].CoVs are members of the Coronaviridae family, which are enveloped viruses that possess large-sized single-strand RNA genomes[23].

Previously, they have been reported as pathogens that only cause mild illnesses in immunocompromised persons until the emergence of the coronavirus that causes severe acute respiratory syndrome (SARS-CoV) in late 2002[24-27]. Presently, at least seven types of coronavirus are known to cause diseases in humans; 229E, OC43, NL63, and HKU1 viruses only cause symptoms of colds, and they are mild. The remaining three viruses can cause severe illness, namely SARS-CoV, which led to the outbreak of SARS in 2002 and 2003 [24,25]; Coronaviruses responsible for Middle East Respiratory Syndrome (MERS-CoV), which appeared in 2012 and are still circulating in camels[28]; and SARS-CoV-2, viruses that appeared in December 2019 in Wuhan, China, and a lot of effort is being made to contain their spread [29].

The Source and Intermediate Host of Coronaviruses

Coronaviruses are zoonotic, which means that viruses are transmitted between animals and humans. Both SARS -CoV and MERS-CoV are known to have originated from Bats and have been transmitted to humans via Civet cats and camel, respectively. By a phylogenetic comparing of SARS-CoV-2 with other CoVs, Bats were considered the original hosts of SARS-CoV-2 as the new virus was 96% identical to two SARS -CoV from Bats called Bat-SL-CoVZX45 and Bat-SL-CoVZX21 [30-33]. However, what intermediate host that helped the virus cross the species barrier to infect humans is still unknown, and the transmission pathway has not yet been clarified [34].

Suggested snakes as a carrier of the virus from bats to humans that involved symmetric recombination

within S protein [34]. According to a study, researchers in Guangzhou, China, suggested that Pangolins - long-snout and ant eating mammals often used in traditional Chinese medicine are the possible intermediate host of SARS-CoV-2 based on 99% of the genetic similarity in a CoV discovered in Pangolins and SARS-CoV-2 [35]. However, the 1% difference prevalent in the two genomes is still a big difference; Consequently, the results of the concrete evidence are awaited (Figure 1).



Figure 1: The natural reservoir, intermediate host, and target in major Coronaviruses [36].

Structure and Classification of Coronaviruses

Coronaviruses (CoVs) are spherical and approximately 125 nm in diameter [37,38], with club-shaped spikes projecting from the surface of the virus giving the appearance of a solar corona, prompting the name, coronaviruses. Within the envelope is the helically symmetrical nucleocapsids, which is uncommon among positive-sense RNA viruses (Figure 2). CoVs are classified under the order Nidovirales, family Coronaviridae, and subfamily Orthocoronavirinae.



Figure 2: Single- Stranded RNA (ssRNA) genome of 26-32 kb for SARS, MERS and novel SARS-2 coronaviruses

(A) with a schematic of the coronaviruses structure: enveloped and spherical particle of around 125 nm in diameter (B) along with respective transmission Electron Microscopy (TEM) images (C) Single-stranded RNA (ssRNA) genome of 26-32 kb for SARS, MERS and novel SARS-2 coronaviruses (A) with a schematic of the coronavirus's structure: enveloped and spherical particle of around 125 nm in diameter (B) along with respective Transmission Electron Microscopy (TEM) images (C) [39].

With genome sizes ranging from 26 to 32 kb in length, CoVs have the largest genome for RNA viruses. Based on genetic and antigenic criteria, CoVs have been classified into four different genera: alphacoronavirus (α-CoV), betacoronavirus (β-CoV), gammacoronavirus (γ-CoV) and delta coronavirus (d-CoV) [40,30]. For SARS-CoV-2, next-generation sequencing also shows 79% homology to SARS-CoV and 50% to MERS-CoV. Phylogenetic analysis has placed SARS-CoV-2 under the subgenus Sarbecovirus of the genus Betacoronavirus (Figure 3) [41].



Figure 3: Classification of Coronaviruses [40,30].

The reservoirs of Coronavirusesare from bats and rodents to the alpha and beta coronaviruses or birds for gamma and deltacoronaviruses [42]. Each CoV genus is organized into subgenera that are currently existing 13, 5, 4, and 2 for an alpha, beta, delta, and gammacoronaviruses, respectively.

Structure of SARS-CoV-2

Virion SARS CoV-2 resembles a solar haloby transmission electron microscopy: the virus particle in a spherical shape with some polymorphism. The diameter of the virus particles ranges from 60 to 140 nm with characteristic spikes of approximately 8 to 12 nm in length[32]. The observed shape of SARS-CoV-2 matches the typical characteristics of the Coronaviridae family. Like other coronaviruses, SARS-CoV-2.

It is including four structural proteins, known as S (spike), E (Envelop), M (membrane) and N (nucleocapsid) proteins; Protein N contains the RNA genome, and S, E, and M proteins together produce the viral sheath (Figure 4).

The spike protein, which was imaged atomic level using a transmission electron microscope [43,44] is the protein responsible for allowing the virus to stick to the membrane of the host cell and integrate it into it [45].



FIGURE 1: Schematic diagram of SARS-CoV-2.



FIGURE 2: Domain comparison overview of Spike Protein S of SARS and SARS-CoV-2. Schematic illustration of SARS-S including functional domains (RBD, receptor binding domain; RBM, receptor binding motif; TD, transmembrane domain) and proteolytic cleavage sites (S1/S2, S2', see arrows). Amino acid sequences around the two protease recognition sites (red) are shown for SARS-S and SARS-2-S (conserved residues are indicated as asterisks).

Figure 4: Schematic diagram of SARS-CoV-2 [45].

Structural protein genes are always maintained in all CoVs. Protein (S) mediates viral binding to specific cell receptors and fusion between the envelope and the plasma membrane and is the main catalyst of virus-neutralizing antibodies. The membrane protein (E) plays an important role in collecting the viral envelope, but it is not necessary for the proliferation of the virus. Membrane Protein (M), the most abundant structural component, is a type III glycoprotein comprising of short an amino-terminal ectodomain, a triple-span transmembrane domain, and a long internal domain of a carboxyl terminal [46,47].

The nucleocapsid protein (N) is an extremely basic phosphorous protein that in addition to its function in virion also modifies the synthesis of viral RNA. In addition to the common group of proteins, CoVs linked to the Betacoronavirus genus, have an additional structural protein, haemagglutinin-esterase (HE), closely related to the haemagglutinin-esterase fusion of the influenza C virus protein. CoVs also have auxiliary genes encoded by extra ORFs located downstream ORF1b. Their number, nucleotide sequence, and arrangement can differ significantly between different CoVs. The function of the extra proteins is unknown in most cases, and as a rule, they are not necessary for the reproduction of the virus. However, they play an important role in virus-host interactions where they are generally preserved during natural infection and their loss - either through spontaneous mutation or reverse genetics - which leads to reduced virulence [46,47].

Genomic Organization of SARS-CoV-2

The genomic sequencing of SARS-CoV-2 was obtained from clinical samples by several laboratories with

profound sequencing [32,33,48-51]. The SARS-CoV-2 genome is like that of typical CoVs, is about 29.8 kb, with a G + C content of 38%, and totaling of six common open reading frames (ORFs) for coronavirus and several other additional genes [33,50]. The 5'-terminal two thirds of the genome ORF1a/b encode two large polyproteins, which form the viral replicase transcriptase complex (Figure 5).



Figure 5: Genomic organization of SARS CoV-2.

The other ORFs of SARS CoV- 2 on the one-third of the genome encode the same four main structural proteins: spike (S), envelope (E), nucleocapsid (N) and membrane (M) proteins, as well as several accessory proteins with unknown functions which do not participate in viral replication. The SARS-CoV-2 viral genome sequence analysis has shown that the genome sequences of viruses from different patients are very conserved [31-33],which means that the human virus is developing recently.

Entry and Life Cycle of SARS-CoV-2

As a member of the Nidovirus family, coronavirus infection (SARS-CoV2) can be transmitted from animals like bats and fellow humans. This virus can enter the human body by its ACE2 receptors which are located in various organs such as the heart, lungs, kidneys, and digestive system, which makes it easier for the virus to enter the target cells. The method of CoV entering the host cell begins by binding to the S glycoprotein receptor, ACE2 in the host cells (such as type II pneumocytes in the lungs) [50].

This binding occurs in the domain of S protein of SARS-CoV-2 receptors that are found at 331 to 524 residues and can be robustly associated with human ACE2 and bats ACE2. Then the entry and attachment processes are followed by fusion of the viral membrane and the host cell. After fusion has occurred, the type II membrane serine protease (TMPRSS2) located on the surface of the host cell will remove ACE2 and activate the receptor attached spike-like S proteins [50]. Activation of S proteins causes configurable changes and allows the virus to enter cells [19]. Both proteins (TMPRSS2 and ACE2) are the central determinants of entry for this virus. Based on research by Sungnak. nasal epithelial cells, specifically the cup/secretory cells and ciliary cells, display the highest expression of ACE2 throughout the respiratory system [3].

Moreover, the inserted SARS-CoV-2 will later release its genomic material into the cytoplasm and become localized in the nuclei.The genomic material released by this virus is mRNA which is ready for translation into a protein. Within its genome, this virus is supplemented by about 14 open reading frameworks (ORF), each of which encodes a different of proteins, both structural and non-structural that play a role in its survival as well as virulence strength. In the transformation stage, the genetic parts that encode non-structural proteins are those that first translate into ORF1a and ORF1b to produce two large superimposed proteins, pp1a and

pp1ab by contributing to the ribosome frameshifting event [5].

Polyproteins are supplemented with protease enzymes, which are papin-like proteases (PLpro) and a serine type Mpro (chymotrypsin-like protease (3CLpro)) protease that encoded in nsp3 and nsp5. Then, the division between pp1a and pp1ab occurs in non-structural proteins (NPSB) 1-11 and 1-16, respectively. Nsps play an important role in many processes in viruses and host cells (Table 1) [9].

Several nsps subsequently form a replicase-transcriptase complex (RTC) in double-membrane vesicles (DMVs), which are fundamentally an aggregation by RNA-dependent RNA polymerase (RdRp) and subunits containing helicase, the resident canonical RdRp domain for CoV nsp12 and AVnsp 9. Moreover, the complex copies the internal genome template of viral entry into negative-sense genes for both the progeny genome and subgenomic RNA as intermediate products followed by transcription into positive-sense mRNAs that are at most mediated by RdRp [10].

Subsequently, the sub-genomic proteins become translated into structural and accessory proteins such as M, S and E proteins that are subsequently isolated into the endoplasmic reticulum and then transferred to the endoplasmic reticulum–Golgi intermediate compartment (ERGIC). Meanwhile, a previously transcribed genome program can directly join N protein in nucleocapsid form and move to ERGIC. In this compartment, nucleocapsids will meet many other structural proteins and form small portfolio vesicles for export outside the cell through exocytosis (Figure 6) [6].



Figure 6: The life cycle of SARS-CoV-2 in host cells.

Coronavirus Disease 2019 (COVID-19) Clinical Manifestation

Clinical manifestations of COVID-19have ranged from asymptomatic mild symptoms to severe disease and death. Common symptoms include fever, cough, and shortness of breath [11]. Other symptoms have also been recorded, such as malaise and respiratory distress [12].

Symptoms may appear two days to two weeks after exposure to the virus [7,11]. Coughing, shortness, or

Table 1: Nonstructural proteins of Coronaviruses and their functions [7].

Function	Nonstructural proteins (nsp)
Inhibition of IFN signals and screening of the host's innate immune response by promoting cellular decomposition and preventing host RNA translation	nsp 1 & 3
Bind to protein prohibition	nsp 2
Promote cytokine expression and cleavage of viral proteins	nsp 3 & 5
Contribution to the structure of DMVs as a trans-membrane scaffold protein (DMVs formation)	nsp 4 & 6
Applied clamp of RNA polymerase by means of a hexadecameric complex	nsp7/8 complex
RNA binding protein phosphatase	nsp 9
inducement of ExoN and 2-O-MT activity	nsp 10,16 & 14
Replication enzyme (RNA-dependent RNA polymerase)	nsp 12
RNA helicase, 5′ triphosphatase	nsp 13
Proofreading of viral genome	nsp 14
Viral endoribonuclease and chymotrypsin-like protease	nsp 15
Avoid recognition with MDA5 and preventing innate immune regulation	nsp 16

difficulty of breath, plus at least two of the following symptoms, may elucidate COVID-19 [11].

- Fever
- Shiver
- Frequent shaking with chills
- Muscle pain
- Headache
- Sore throat
- New loss of taste or smell

Other recorded symptoms have included the following:

- Fatigue
- Sputum production
- Diarrhea
- Malaise
- Respiratory distress

Wu and Macogogan recorded that of the 72,314 Covid-19 cases reported to the Chinese Center for Disease Control and Prevention (CCDC), 81% were mild (missing or light pneumonia), and 14% were intense (hypoxia, dyspnea,>50% Lung involvement during 24-48 hours), 5% were crucial (shock, respiratory failure, multi-organ dysfunction), and 2.3% were lethal [13].

In a preliminary report of 41 affected patients in Wuhan, China, that the most common clinic outcome was fever (98%), followed by cough (76%) and muscle pain and fatigue (44%). Headaches, sputum production and diarrhea were less common. The clinical course was described by the development of dyspnea in 55% of patients and the lack of lymphocytes(lymphopenia) in 66%. All patients with pneumonia have abnormal imaging results for the lung. Acute respiratory distress syndrome (ARDS) developed in 29% of patients [1], and ground glass opacity are common on CT scans [50].

Symptoms in infected children appear to be uncommon, although some children with severe COVID-19 have been notified).Asymptomatic infections have been recorded, but the incidence is unknown [50]. A

complete or partial loss of smell sensation (anosmia) has been reported as a possible historical discovery for patients eventually diagnosed with COVID-19[50]. A survey of outpatients with mild symptomatic COVID-19 found that 64.4% (130 of 202) reported any changed sense of smell or taste. In a European study of 72 patients with positive PCR results for COVID-19, 53 patients (74%) reported decreased olfaction, while 50 patients (69%) reported a decreased sense of taste. Forty-nine patients (68%) reported both symptoms [9].

Risk factors: The risk factors of severe COVID-19 include (but are not restricted to) the following [33]:

- Advanced age
- Immuno compromised condition
- Diabetes
- Cardiovascular diseases
- Hypertension
- Chronic lung disease
- Chronic kidney disease
- Liver disease
- Malignancy
- Severe obesity

Patients suspected with COVID-19 should be reported as soon as to infection control personnel at their health care facilities, local or state health department. Current CDC guideline calls for patient care with airborne and contact precautions (including eye shield) in the site. Patients nominees for such reports include those with fever and symptoms of lower respiratory disease who have traveled from Wuhan, China, during the previous 14 days or who have been communicatec with a person under investigation of COVID-19 or a patient with laboratory assuredCOVID- 19 in the previous 14 days.

Complications: Complications of patients with coronavirus disease 2019 (COVID-19) include the following [7]:

- Pneumonia
- Hypoxemic respiratory failure/acute respiratory distress syndrome (ARDS)
- Diffuse alveolar damage
- Secondary bacterial infections
- Sepsis and septic shock
- Cardiac injury
- Cardiomyopathy
- Arrhythmia
- Sudden cardiac death
- Acute kidney injury
- Acute Liver injury
- Multiorgan failure

Pneumonia: The extremely high incidence of pneumonia was the first sign of a new coronavirus in

China. When patients have pneumonia, the air sacs in his lungs become inflamed, which makes breathing more difficult.

Scientists who have studied images of the lungs of patients with severe COVID-19 found them filled with fluid, pus, and debris of cells. In those cases, the patients' bodies were unable to transfer oxygen to the blood to keep their systems working properly[7].

Acute Respiratory Distress Syndrome(ARDS): The alveolar cells in the lung contain considerable amounts of ACE2, allowing COVID-19 to be housed within the alveoli. About 41.8% of patients suffer from acute respiratory distress syndrome (ARDS). Diabetes mellitus is a factor related to the development of ARDS. Other associated diseases include high blood pressure, cardiovascular disease, and chronic kidney disease. Laboratory results associated with the development of ARDS include neutropenia, lymphocytosis, elevated C-reactive protein (high and normal sensitivity), elevated blood urea nitrogen, dimer elevation, long-term PT, and high LDH. Patients with ARDS are present with high levels of lactate and score high in stratified calculators for common risks[36].

About 35.8%, 45.3% and 18.9% of ARDS cases are mild, moderate, and severe; respectively. The death rate increases with the severity of the disease. Patients over 65 years of age have worse degrees of ARDS and have a higher risk of death. Laboratory signs that predict mortality for COVID-19 ARDS patients include low albumin, high urea nitrogen levels in the blood, and high LDH [9].

Heart Fears: The increasing data showed a significant burden of heart injury in COVID-19. Up to 20% of patients in a group in China showed a heart attack, often associated with a more serious disease. They were more likely to be older, to have ARDS, and to have higher mortality rates [14].

Another studyhas published excellent reviews outlining current understanding and future investigation needs. A series of multiple cases observed an increase in the burden of cardiovascular disease (4%-14%) and cardiovascular disease in patients with COVID-19, often related to increased morbidity and mortality[42].

The risk of developing heart disease, as demonstrated by increased troponin levels, was 22% in ICU patients. Interestingly, up to 12% of patients who do not have known cardiovascular disease have elevated COVID-19. The pathophysiology of the injury is under investigation, but some symptoms appear to be related to the cytokine storm.

In a study of 21 patients with severe COVID-19 who were admitted to the intensive care unit in Washington state, reported that 33% had cardiomyopathy. levels of troponin or have had a heart attack during hospitalization.

Secondary Bacterial Infection: Secondary infection means that patients get an infection that has not connected with the first problem that he suffered from. In this case, this means that someone with COVID-19 gets something else [14].

A review of several studies conducted to date on hospital patients with COVID-19 found that secondary infection is possible, but not a common complication. Sometimes, someone resists, or recovers from the virus are infected withbacteria such as Streptococcus bacteria and Staphylococcus aureus which are common causes. This can be dangerous enough to raise the risk of death [10].

Septic Shock: Sepsis occurs when the body's reaction to the infection fails. The chemicals that are released into the bloodstream to fight disease do not lead to the correct response, and instead, the organs will be damaged. If the process does not stop, it can lead to the so-called septic shock. If the blood pressure drops too much, a septic shock can be fatal. Septic shock affected some people with COVID-19 in China [15].

Arrhythmia: The relationship of COVID-19 to inducing heart arrhythmias can be due to acute heart injury from various causes such as hypoxia mediated, exacerbation of coronary artery perfusion, direct tissue damage, or a product of acute hyperinflammatory response syndrome or it may be due to the effects of drugs used in COVID-19 management. In one study, about 16.7% of people had arrhythmias, with an increase to 44.4% of those admitted to the intensive care unit [9]. There is concern about hypokalemia in COVID-19 disease. The result of SARS-CoV2 interaction with the RAS system [11].

Acute Kidney Injury: Acute kidney injury appears with elevated urea and cystatin C levels appear in severe COVID-19 infection [20]. There are two hypotheses regarding the cause of acute kidney injury. One of them is from the kidneys that have more ACE2 levels than the lung or heart, especially in the proximal twisted tubes. However, COVID-19 RNA is not found in the urine. The other theory of injury during a cytokine storm. Patients can get a continuous renal replacement therapy (CRRT) based on the severity of kidney injury. There is speculation regarding CRRT that could serve to remove large levels of cytokine from the system, regardless of kidney injury.

Acute Liver Injury: Research appears that more serious patients are at greater risk of liver damage. Scientists are not yet sure whether the virus is harmful to the liver or if it occurs for another reason. Acute liver injuries and liver failure are life-threatening complications [14].

Disseminated Intravascular Coagulation: When disseminated intravascular coagulation, or DIC, the blood clotting response in the body is not working properly. Abnormal clots form, which can lead to internal bleeding or organ failure. In one study of Chinese COVID-19 patients, DIC was common among those who died [15].

Differences Between COVID-19, Common Cold, and Flu

The common cold is caused by countless viruses. Most are Rhinoviruses and benign forms of coronaviruses. Cold and COVID-19 have a progressive course of symptom manifestation compared to flu caused by different influenza strains (Orthomyxovirus family). Pyrexia is rare in colds but is a common symptom in both COVID-19 and influenza. Cough and fatigue are rare in the common cold. Common cold symptoms such as the runny nose and nasal congestion are prevalent in the common cold and are rare in influenza and COVID-19 [42].

COVID-19 appears like flu as both are respiratory diseases. In both diseases, the clinical manifestation can differ from asymptomatic to severe pneumonia. Moreover, COVID-19 and influenza are transmitted by contact, droplets, and vomit. Therefore, similar hand hygiene and respiratory etiquette techniques will be useful in preventing proliferation. Another factor affecting the prevalence of any infection is the primary reproductive number (R_o). The flu virus contains R_o~1.3 while the SARS-CoV-2 virus has R_o~2.3. Therefore, each COVID-19 patient can spread 1.8 times more new contacts than influenza patients [25].

Compared to SARS (caused by SARS - CoV-1 virus), some patients with COVID-19 (caused by the SARS virus - CoV-2) can be contagious during the incubation period even in their asymptomatic stage. The elapsed time from the onset of exposure to pathogens to the clinical manifestations of the disease is called the incubation period. Table 2 shows variability in incubation periods for each coronavirus and orthomyxovirus. The larger incubation of COVID manifestations along with the ability to transmit infection during this period demonstrates how quickly SARS-CoV-2 can spread.

Table 2: Summary of incubation times of various coronaviruses and orthomyxovirus.

Virus Family	Virus (Disease)	Incubation Period	References
Coronavirus	SARS-CoV-2 (COVID-19)	2-14 days	-86
	SARS –Cov-1 (SARS)	2-7 days	-87
	MERS-CoV (MERS)	5 days	-88
Orthomyxovirus	H1N1 Influenza A (swine flu)	1- 4 days	-89
	Influenza A (Seasonal flu)	2 days	-84

References

1. World Health Organization (2020) Novel Coronavirus (2019-nCoV): situation report. 22nd Report.

2. Huang P (2020) How does Wuhan Coronavirus compare with MERS, SARS and the common cold?. NPR.

3. Fox D (2020)What you need to know about the Wuhan coronavirus. Nature.https://doi.org/10.1038/d41586-020-00209-y

4. Yam K (2020) GOP lawmakers continue to use ‘Wuhan virus’ or ‘Chinese coronavirus. NBC News.

5. Marquardt A, Hansler J (2020) US push to include ‘Wuhan virus’ language in G7 joint statement fractures alliance.CNN.

6. Wuhan virus sees Olympic football qualifiers moved. Xinhua.

7. World Health Organization (2020) Novel Coronavirus (2019-nCoV): situation report. 10th Report.

8. World Health Organization (2015) World Health Organization best practices for the naming of new human infectious diseases.

9. Novel coronavirus named Covid-19: WHO. Today online.

10. The coronavirus spreads racism againstand amongethnic Chinese. The Economist.

11. Hui M (2020) Why won’t the WHO call the coronavirus by its name, SARS-CoV-2?. Quartz.

12. World Health Organization (2020) Naming the coronavirus disease (COVID-2019) and the virus that causes it.

13. From a risk communications perspective, using the name SARS can have unintended consequences in terms of creating unnecessary fear for some populations. For that reason and others, WHO has begun referring to the virus as “the virus responsible for COVID-19” or “the COVID-19 virus” when communicating with the public. Neither of these designations are (sic) intended as replacements for the official name of the virus as agreed by the ICTV.

14. Morgan G (2020)WHO official warns against calling it ‘Chinese virus’, says ‘there is no blame in this’. The Hill.

15. Paul S (2020) Trump fires back at complaints he’s stigmatizing China over coronavirus. US News.

16. Donald Trump drops ‘Chinese virus’ terminology in White House briefing, calls for protecting Asian-Americans. South China Morning Post.

17. Yousif NG (2014) Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK–PI 3 K/A kt pathway.Cell Biol Int 38:85-91.https://doi.org/10.1002/cbin.10184

18. Wang LF, Shi Z, Zhang S, Field H, Daszak P, et al.(2006) Review of bats and SARS. Emerg Infect Dis12:1834-1840.https://dx.doi.org/10.3201/eid1212.060401

19. Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, et al. (2013) Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature503:535-538.https://doi.org/10.1038/nature12711

20. Chen Y, Guo D (2016) Molecular mechanisms of coronavirus RNA capping and methylation. Virol Sin31:3-11.https://doi.org/10.1007/s12250-016-3726-4

21. Su S, Wong G, Shi W, Liu J, Lai AC, et al. (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol24:490-502.https://doi.org/10.1016/j.tim.2016.03.003

22. Zhong NS, Zheng BJ, Li YM, Poon LL, Xie ZH, et al. (2003) Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet362:1353-1358.https://doi.org/10.1016/S0140-6736(03)14630-2

23. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med348:1967-1976. https://doi.org/10.1056/NEJMoa030747

24. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, et al. (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med348:1953-1966.https://doi.org/10.1056/NEJMoa030781

25. Fouchier RA, Kuiken T, Schutten M, Van Amerongen G, Van Doornum GJ, et al. (2003) Koch’s postulates

fulfilled for SARS virus. Nature423:240. https://doi.org/10.1038/423240a

26. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med367:1814-1820. https://doi.org/10.1056/NEJMoa1211721

27. Zhu N, Zhang D, Wang W, Li X, Yang B,et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382: 727-733.https://doi.org/10.1056/NEJMoa2001017

28. Dong N, Yang X, Ye L, Chen K, Chan EW, et al. (2020) Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. BioRxiv.https://doi.org/10.1101/2020.01.20.913368

29. Xu X, Chen P, Wang J, Feng J, Zhou H, et al. (2020) Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 63: 457-460.https://doi.org/10.1007/s11427-020-1637-5

30. Lu R, Zhao X, Li J, Niu P, Yang B, et al.(2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet395: 565-574.https://doi.org/10.1016/S0140-6736(20)30251-8

31. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. (2020) Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. BioRxiv.http://dx.doi.org/10.1038/s41586-020-2012-7

32. Ji W, Wang W, Zhao X, Zai J, Li X(2020) Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol 22: 1-8.

33. Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, et al. (2020) Isolation and characterization of 2019-nCoV-like coronavirus from Malayan Pangolins. BioRxiv.https://doi.org/10.1101/2020.02.17.951335

34. Kakodkar P, Kaka N, Baig MA (2020) Comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus12: e7560.https://dx.doi.org/10.7759/cureus.7560

35. Neuman BW, Adair BD, Yoshioka C, Quispe JD, Orca G, et al. (2006) Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J Virol80:7918-7928. https://doi.org/10.1128/JVI.00645-06

36. Bárcena M, Oostergetel GT, Bartelink W, Faas FG, Verkleij A, et al. (2009) Cryo-electron tomography of mouse hepatitis virus:Insights into the structure of the coronavirion. Proc Natl Acad Sci U S A 106: 582-587.https://doi.org/10.1073/pnas.0805270106

37. Schoeman D, Fielding BC (2019)Coronavirus envelope protein: current knowledge. Virol J 16: 1-22. https://doi.org/10.1186/s12985-019-1182-0

38. van Regenmortel MH, Fauquet CM, Bishop DH, Carstens EB, Estes MK, et al. (2000) Virus taxonomy: Classification and nomenclature of viruses Seventh report of the International Committee on Taxonomy of Viruses.Academic Press, San Diego, California, United States.

39. Mandelbaum RF (2020) Scientists create atomic-level image of the new coronavirus's potential Achilles heel. Gizmodo.

40. Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, et al. (2012) Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 86: 3995-4008.https://doi.org/10.1128/JVI.06540-11

41. Lorusso A, Calistri P, Petrini A, Savini G, Decaro N (2020) Novel coronavirus (SARS-CoV-2) epidemic:a

veterinary perspective. Vet Ital56:5-10.https://doi.org/10.12834/vetit.2173.11599.1

42. Li Q, Guan X, Wu P, Wang X, Zhou L,et al. (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med382:1199-1207.https://doi.og/10.1056/NEJMoa2001316

43. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, et al. (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science367: 1260-1263.https://doi.org/10.1126/science.abb2507

44. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, et al. (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B10: 766-788.https://dx.doi.org/10.1016/j.apsb.2020.02.008

45. BrianDA,Baric RS (2005) Coronavirus genome structure and replication. CTMI 287:1-30.https://doi.org/10.1007/3-540-26765-4_1

46. Decaro N, Desario C, Elia G, Martella V, Mari V, et al.(2008) Evidence for immunisation failure in vaccinated adult dogs infected with canine parvovirus type 2c. New Microbiol 31: 125-130.

47. Chan JF, Kok KH, Zhu Z, Chu H, To KK, et al. (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect9:221-236.https://doi.org/10.1080/22221751.2020.1719902

48. Chen L, Liu W, Zhang Q, Xu K, Ye G, et al. (2020) RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect9:313-319.https://doi.org/10.1080/22221751.2020.1725399

49. Chan JF, Yuan S, Kok KH, To KK, Chu H, et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet395:514-523.https://doi.org/10.1016/S0140-6736(20)30154-9

50. Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD (2020) SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens9:231.https://doi.org/10.3390/pathogens9030231

51. Tai W, He L, Zhang X, Pu J, Voronin D, et al. (2020) Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 17: 613-620.https://doi.org/10.1038/s41423-020-0400-4

Chapter -2

Epidemiology of COVID-19

Epidemiology and Transmission

The COVID-19 scourge extended in early December from Wuhan, China's 7th most populous city, all through China and was at that point sent out to a developing number of nations. The primary confirmed case of COVID-19 exterior China was analyzed on 13th January 2020 in Bangkok (Thailand) on the 2nd of March 2020, 67 regions exterior territory China had detailed 8565 affirmed cases of COVID-19 with 132 deaths, as well as critical community transmission happening in several countries around the world, counting Iran and Italy.

On the 11th of March WHO announced COVID-19 A global pandemic due to an increase in cases 13-fold and a fatality rate of more than 17000 in overall the world. The number of affirmed cases is continually expanding around the world and after Asian and European locales, increment in cases is. It is risky to evaluate the precise size of this pandemic because it would necessary to tally all cases counting not as it were extreme and symptomatic cases but too mellow ones Unfortunately, to date, there's not a worldwide and standard reaction to the pandemic and each nation is facing the emergency based on their possess conceivable outcomes, mastery and theories.

Hence, there are different criteria for testing, hospitalization and evaluating of cases making it troublesome to calculate the number of people influenced by infection. Based on the information we have so distant, the evaluated case casualty proportion among medically gone to patients is roughly 2%, but, moreover, in this case, a genuine proportion may not be known for a few times.

The epidemiology in Asia as it realizes that covid-19 has been raised. In late December 2019, a group of patients was admitted to medical clinics with an underlying determination of pneumonia of an obscure etiology. These patients were epidemiologically connected to a fish and wet animal wholesale market in Wuhan, Hubei Province, China. Then the virus spread widely through the continent. As of 17 May 2020, at least one case of COVID-19 had been reported in every country in Asia except North Korea and Turkmenistan.

Nations with the most of the highest numbers of affirmed coronavirus cases are Turkey, Iran, India, China, and Saudi Arabia. Among the most nations to report COVID-19 cases after the episode in China were South Korea and Taiwan, however, these nations have effectively controlled the pandemic. The most noticeable quantities of passings are recorded in Iran, China, Turkey, India, and Indonesia, with more than 20,000 deaths consolidated. The losses of life in various nations, in any case, are professed to be fundamentally higher than those given in the declared data [1].

Asian nations experienced a critical rise in cases taking after a Tabligh Jamaat occasion from 27 February to 1 March at a mosque in Kuala Lumpur, where numerous individuals are accepted to have been infected. Additionally, occasions in India and Pakistan have moreover caused a surge within the number of cases in those nations. Major episodes developed in dormitories for transient specialists within the Maldives and Singapore where social removing was incapable to be practiced and driven to a critical rise in cases.

The infection spread to Russia on 31 January 2020, when two Chinese citizens in Tyumen, Siberia and Chita, Russian Distant East tried positive for the virus, with both cases being contained. Early avoidance measures included limiting the border with China and broad testing. The disease spread from Italy on 2 March, driving to extra measures such as canceling occasions, closing schools, theaters, and galleries, closing the border, On 27 April, the number of affirmed cases outperformed those in China. Russia was generally late in suffering confirmed cases but presently has gotten to be the nation with the third-most cases within the world, after the U.S and Brazil. Agreeing to official figures as of 28 May, Russia has 379,051

affirmed cases, 150,993 recoveries, 4,142 deaths, and over 9.7 million tests performed. Moscow is right now the foremost influenced city in the country.

COVID-19 is Pandemic in Europe

After China, COVID-19 experienced advance topographical spread. the first three reported cases were in France on 24 January 2020 in people returning from Wuhan, Hubei Area, China, and then at last February, the cases increased to 342 with 50 cases per day. As of 15 March 2020, COVID-19 cases had been recognized in all 30 EU/EEA nations and the UK, whereby between 31 December 2019 which date included, 39,768 cases and 1,727 deaths had been detailed, with 17,750 cases and 1,441 deaths from Italy alone.

The epidemiological data demonstrate that the number of informed cases of COVID-19 is quickly expanding within the EU/EEA and the UK. The watched patterns within the aggregate frequency of COVID-19 recommend that the widespread is progressing at a comparable speed in all nations. This can be despite nations being at diverse stages, varieties in national open wellbeing reactions, and conceivably diverse case definitions in nations and diverse conventions for selecting patients that must be tried for affirmation of COVID-19, counting catch-up testing, In March 2020, specialists within the influenced locales of Italy depicted a circumstance in which 10% of cases with COVID-19 required serious care. and media sources detailed that healing centers and seriously care units in these locales had exhausted Their greatest capacity. Information about cases in a clinic and/or an intensive care unit are as of now accessible at EU/EEA level for as it were 6% and 1% cases, separately (information not appeared).

They ought to, in any case, be collected in a precise mold to complement current observation information that centers on the number of detailed cases and the number of deaths. a ponder performed in 2010-11 showed a huge variety within the accessibility of seriously care and middle care beds in Europe, extending from 29.2 in Germany to 4.2 beds per 100,000 populaces in Portugal. This implies that nations may have assets than Italy (12.5 seriously care and middle of the road care beds per 100,000 populaces in 2010-2011).

Mode the involvement from Italy and the current patterns in other nations appear that the COVID-19 widespread is advancing quickly within the EU/EEA and the UK. Nations, clinics and seriously care units ought to hence plan themselves for a situation of maintained community transmission of SARS-CoV-2 and an increment within the number of patients with COVID-19 requiring healthcare, and in particular intensive care, such as the one happening within the influenced districts of Italy.

As pointed out within the later ECDC fast chance appraisal, a quick, proactive and comprehensive approach is basic to delay the spread of SARS-COV-2, with a move from a control to a moderation approach, as the expected fast increment within the number of cases may not give choice creators and healing centers sufficient time to comprehend, acknowledge and adjust their reaction appropriately if not executed ahead of time. The quick chance evaluation too records the open wellbeing measures to moderate the effect of the widespread.

There's a short window of opportunity amid which nations have the plausibility to advance increment their control endeavors to moderate down the spread of SARS-CoV-2 and diminish the weight on healthcare. Falling flat this, it is likely that the healthcare frameworks of other EU/EEA nations will confront a surge of patients that require seriously care inside the coming days or weeks COVID-19.

In the USA the primary known human-to-human transmission of SARS-CoV-2 was distinguished in late January 2020. An infected woman in her 60s returned from Wuhan and subsequently became symptomatic and transmitted the infection to her husband with whom she had delayed and unprotected contact. An examination of 350 contacts of both patients did not lead to any extra cases. However, we cannot run the show out the plausibility that some asymptomatic contacts went undetected, since the proportion of asymptomatic COVID-19 cases appears to be huge. For the case, the assessed asymptomatic proportion was 18% for the episode on the Diamond Princess Journey ship, On March 15, a state of emergency was declared in the United States of America, where the rate of injuries reached 3499, which included 60 deaths. Most cases have been reported in New York (20.1%), Washington (18.4%), and California (12.2%), but the epidemic is still unraveling as testing becomes broadly available across the country.

Now-a-days more than 1,707,700 individuals within the Joined together States have been contaminated with the coronavirus and at slightest 100,400 have died, as regarding the New York Times database.

Pandemic in the Africa

Africa is the final major territory to surrender to the SARS-CoV-2 pandemic. The primary confirmed case within the locale was detailed on February 14, but what lies ahead in terms of the course and greatness of the infection remains speculative. To the finest of our knowledge, no ponder, employing a strong technique, gives the quick and long-term direction of COVID-19 for the whole locale or accounts for its nearby setting.

Early COVID-19 cases in Africa were generally imported from Europe, due to the higher volume of commerce and tourism aircraft activity between African nations and Europe, and less from China. The first case was detailed in Egypt on Feb 14, 2020, (a grown-up male whose 17 contacts tried negative) and prompted African readiness endeavors.

In South Africa, on Feb 29, 2020, when nine old age passengers returned from a skiing occasion in Italy, where the COVID-19 epidemic was uncontrolled. After creating a flu-like illness, one of them was positive for COVID-19, which was affirmed by RT-PCR on March 5, 2020; his spouse was asymptomatic but tried positive on March 8, 2020. Early estimates of case fatality rates (CFRs) seem to change significantly. as of April 24, 2020,

South Africa had detailed 3635 cases with 65 deaths (CFR 1.8%) and Senegal had detailed 442 cases with 6 deaths (CFR 1.3%). These CFRs appear lower than in most European nations (e.g., Italy had detailed 187 327 cases).

In Australia

Twelve cases of infection were informed up until 1 February 2020; All twelve cases detailed a travel history to China, and 92% (11/12) had a travel history to Wuhan, Hubei Province, China; The lion's share of cases (92%, 11/12) developed gentle to direct symptoms, with one case (8%, 1/12) admitted to intensive care; Zero deathswere detailed; and • Two days passed since the onset of ailment within the most recent affirmed case and the date of this report.

In May the rate of modern cases of COVID-19 has reduced significantly since a top in mid-March. Social distancing measures, open health action and the lessening in universal travel have likely been viable in abating the spread of the disease within the Australian community according toCOVID-19 National Incident Room Surveillance Team.

The Epidemiology in the Middle East

It is difficult to foresee the course of the COVID-19 pandemic in locales such as the Middle East and Africa, where epidemic spread shows up to still are restricted. But current official numbers in Middle Easterner nations, which drop distant behind those within the US, Spain and Italy, for illustration, maybe a reflection of a delay in the presentation of the infection as a result.

Another reason may be the lower levels of testing and announcing in a few Middle Easterner nations. Lower salary nations will not have adequate assets to scale up testing, will have restricted research facility capacity, and frail reconnaissance frameworks. This implies there could be an undocumented transmission. Differentials in testing are watched indeed inside locales and are ordinarily connected to accessible assets.

For illustration, numerous of the Middle easterner Inlet nations, such as the UAE, Bahrain, and Qatar, rank among the most elevated within the world in terms of the number of tests per one million individuals, whereas the rest of the Middle easterner world has conducted small testing, comparatively. It isn't shocking that these three nations have the most elevated number of detailed cases per one million occupants within the districts.

Many hypotheses almost the potential impact of regularity and hotter climate on the spread of the infection, with a few contending that the scourge has not spread much within the African landmass since of hotter climate. In any case, the impact of regularity is still not known. Indeed, in case a hotter climate might moderate the spread of the contamination, it is impossible that, alone, this could avoid an epidemic from happening. Typically, particularly appropriate within the case of SARS-CoV-2 disease, the infection causing COVID-19, due to its tall generation number (R0) of around 2.5, compared with regular influenza's R0 of almost 1.3. The propagation number is the normal number of auxiliary contaminations caused by one tainted individual at the starting of a plague. It gives a sign of the inborn potential of an irresistible specialist to spread in a given populace.

The delay within the general timeline of the worldwide epidemic has given nations with a window of opportunity for the early presentation of anticipation mediations. A few Middle easterner nations have begun forcing early control measures as a response to the emergencies that were taking put in more progressed nations such as Italy, the US, and Spain. Numerous Middle Easterner nations are mindful of their inadequacy to bargain with such a quickly developing plague.

For illustration, even though Lebanon was going through a troublesome financial emergency amid a popular uprising, the government reported school closures without further ado after the primary few cases were recorded, and forced a lockdown when the number of cases rose to fair underneath 100. Jordan moreover forced strict border controls in no time after the primary case was archived, at that point taken after this with a lockdown of the populace.

At last, whereas mortality is influenced by the quality of care, the right now watched more death rates in a few Middle Easterner nations could be clarified by the defensive impact of age. Based on distributed epidemiological prove, the seriousness of COVID-19 has solid joins to progressed age. The extent of cases that create extreme or basic malady increments consistently with age.

The statistic profile in developing countries, in terms of age structure, is exceptionally distinctive compared to creating nations. The last mentioned, counting most of the Arab world, have much more youthful populaces, and may well be anticipated to have less basic illness cases and subsequently lower mortality.

Italy, which has archived a high death toll, has one of the most seasoned populaces within the world. Be that as it may, one has to be beyond any doubt that it may take up to eight weeks taking after the beginning onset of indications sometime recently individuals create basic complications and deaths Since the contaminations in Middle easterner nations might be slacking behind those in other districts, it may be untimely to think that mortality is more in this portion of the world.

Transmission

Coronaviruses including COVID-19 can be transmitted through beads of various sizes: when the droplets particles are >5-10 μm in width they are entering to as respiratory drops, and when at that point are <5μm in distance across, they are alluded to as bead nuclei. According to ebb and flow proof, COVID-19 infection is principally transmitted between individuals through respiratory drops and contact routes [2-7]. In an examination of 75,465 COVID-19 cases in China, the airborne transmission was not reported (Figure 1).



Figure 1: York Time's database.

Airborne transmission is not quite the same as bead transmission as it alludes to the nearness of organisms inside bead cores, which are commonly viewed as particles <5μm in width, can stay noticeable all around for extended periods of time and be transmitted to others over separations more prominent than 1m.

With regards to COVID-19, the airborne transmission might be conceivable in explicit conditions and settings in which methodology or bolster medicines that create mist concentrates are performed; i.e., endotracheal intubation, bronchoscopy, open suctioning, organization of nebulized treatment, manual ventilation before intubation, turning the patient to the inclined position, detaching the patient from the ventilator, non-obtrusive positive-pressure ventilation, tracheostomy, and cardiopulmonary revival [8,9].

Bead transmission happens when an individual is in close contact (inside 1m) with somebody who has respiratory side effects (e.g., hacking or sniffling) and is in this manner in danger of having his/her mucosae (mouth and nose) or conjunctiva (eyes) presented to conceivably infective respiratory beads. Transmission may likewise happen through fomites in the prompt condition around the tainted person. Therefore, the transmission of the COVID-19 infection can happen by direct contact with contaminated individuals and aberrant contact with surfaces in the quick condition or with objects utilized on the tainted individual (e.g., stethoscope or thermometer). There is some proof that COVID-19 contamination may prompt intestinal disease and be available in dung. Be that as it may, to date just one investigation has refined the COVID-19 infection from a solitary stool specimen. There have been no reports of fecal–oral transmission of the COVID-19 infection to date.

References

1. World Health Organization (2020) Novel coronavirus (2019-nCoV):situation report. 1st report.

2. Hsu LY, Chia PY, Lim JF (2020) The novel coronavirus (SARS-CoV-2) epidemic. Ann Acad Med Singap49:1-3.

3. World Health Organization (2020) Coronavirus disease 2019: situation report. 66th report.

4. Lipsitch M, Swerdlow DL, Finelli L (2020) Defining the epidemiology of covid-19-Studies needed. NEnglJ Med382:1194-1196.https://doi.org/10.1056/NEJMp2002125

5. Lipsitch M, Donnelly CA, Fraser C, Blake IM, Cori A, et al. (2015) Potential biases in estimating absolute and relative case-fatality risks during outbreaks. PLoSNegl Trop Dis 9: e0003846.https://doi.org/10.1371/journal.pntd.0003846

6. Achoki T, Alam U, Were L, Gebremedhin T, Senkubuge F,et al. (2020)COVID-19 pandemic in the African continent: forecasts of cumulative cases, new infections, and mortality. medRxiv.https://doi.org/10.1101/2020.04.09.20059154

7. Mehtar S, Preiser W, Lakhe NA, Bousso A, TamFum JJ, et al. (2020) Limiting the spread of COVID-19 in Africa: one size mitigation strategies do not fit all countries. Lancet Glob Health 8: e881-e883.https://doi.org/10.1016/S2214-109X(20)30212-6

8. COVID-19 National incident room surveillance team 2020.https://doi.org/10.33321/cdi.2020.44.14

9. Chowell G, Mizumoto K (2020) The COVID-19 pandemic in the USA: what might we expect?. Lancet 395: 1093-1094.https://doi.org/10.1016/S0140-6736(20)30743-1

Chapter -3

Molecular Changes of SARS-COV-2 Genome and Emergent of New Variants

Introductory Remarks

The novel coronavirus (SARS-CoV-2 or 2019-NcoV) named according to the disease caused severe acute respiratory syndrome and because they having high genomic homology (> 80%) to the previous one SARS-CoV acute respiratory distress syndrome (ARDS) which spread in the middle east during 2002-2003 [1]. originally, the outbreak of COVID-19 was from some animal, so it is of zoo origin. However, later an important outbreak occurs and human to human transmission happens [2].

Also, it is initially originating as an epidemic then becomes a pandemic which was declared by the World Health Organization (WHO). Now, COVID-19 impact many people and cause an economic burden worldwide [3,4]. More than 200 countries were medically and economically effected according to the Center for Systems Science and Engineering (CSSE) at John Hopkins University [5].

Medically, the SARS-CoV-2 virus mainly affects the respiratory system and causing the disease named COVID-19, but other systems could also involve. Symptoms including fever, dry cough, and dyspnea were detected [6]. Moreover, headache, dizziness, weakness, vomiting, and diarrhea were also noticed [7]. However, the disease could be fatal. Epidemiological studies have reported that mortality is higher in older people rather than children [8]. Now only medical management is available and no known targeted therapy is discovered. Several drugs including lopinavir-ritonavir, remdesivir, hydroxy-chloroquine, and azithromycin have been tested but none have been proven as therapy [8-10].

Moreover, no vaccine was developed yet due to the molecular changes occur on the genome during recombination and the number of variants produced which cause a new outbreak [11]. Here, we will review genomic organization, replication, and molecular changes by recombination as well as possible successive mutations which cause the emergence of new variants and strains which allow later spread of the virus as a pandemic.

Terminology

The term coronavirus was first specified as a virus having spike-like projections, "crown", which is mimic the crown or wreath, a word which borrowed from Greekκορώνη korṓnē [12]. The first scientist June Almeida and David Tyrrell used that term when studied human coronaviruses. In the journal of "Nature", the word was first used in a scientific paper by a group of virologists in 1998 to specify the emergence of a new family of viruses [13].

The term used to describe some characteristics of the infective form (virion) as visualized by an electron microscope, which has unique bulbous form projection (peplomeric spike), later it was known that these projections are proteins molecule anchored on the surface of the lipid bilayer membrane [14].

Disease History

The first time, some veterinary specialist diagnoses an acute respiratory infection of chickens, they recognized the cause as infectious bronchitis virus (IBV) [15]. Moreover, in 1931, Hawn described another new respiratory disease also infected chicken in North Dakota. However, it is diagnosed as gasping and listlessness. It was aggressive, the mortality could be reached to 90% [16]. Six years later, Fred Beaudette and Charles Hudson were able to isolate and successfully cultivate the virus [17]. Ten years later, other coronaviruses were isolated, which are mouse hepatitis virus (MHV) and gastroenteritis virus (TGEV) [18].

But at that time, they were not realized that they are related [19].

Previously, it was not known at that time coronaviruses could be transmissible to human till 1960 [20]. Two different strategies were followed to isolate human coronaviruses, the first at Common Cold Unit of the British Medical Research Council by E.C. Kendall, Malcolm Byone, and David Tyrrell in the United Kingdom. They have successfully isolated a new common cold virus designated as B 814 [21]. They fail to cultivate the virus using known standard methods. However, Tyrrell and Bone in the United State were able to cultivate the virus using a new technique. They prepare an organ culture of the human embryonic trachea and passing the virus through [22].

Later, this cultivation method was used by the lab of Bertil Hoorn as a new technique [23]. Moreover, a new method was introduced in vivo. When the isolated virus intranasal introduced into some volunteers causing a cold in them, they inactivated the virus by ether which affects the lipid and that proves, the virus had a lipid envelope [24]. In the United State at the University of Chicago, Dorothy Hamre [25] and John Procknow were able to isolate a new cold virus designated as 229E which was grown in kidney tissue culture. The strain 229E, mimic the previous one B814, it is also causing cold in volunteers and also inactivated by ether [26].

In 1967, the new strains (B814 and 229E) were studied in detail using electron microscopy at St. Thomas Hospital in London by June Almeida. He was able to show that strain B814 and 229E are morphologically related depending on their spikes. They are also related to the infectious bronchitis virus (IBV) [27]. At the National Institute of Health, at that time a group succeeded in isolating another new virus using the same technique (organ culture) and designated it as strain OC43. This strain also has a spike-like structure when visualized under an electron microscope [28].

Later, the strain IBV was also found to be related to the mouse hepatitis virus [29]. All those groups were collectively put under a name coronavirus after electron microscope imaging [14]. These two strains 229E and OC43 continued to be studied by interested groups [30]. However, the strain B814 was lost during sub-culturing [31]. Other human coronaviruses have been identified, when spread occur which were designated as SARS-CoV in 2003, HCoV NL63 in 2004, HCoV HKU1 in 2005, MERS-CoV in 2012, and SARS- CoV-2 IN 2019 [11].



Figure 1: Schematic representation of SARS-CoV-2 components.

Molecular Virology

Morphology and Structure

In general coronaviruses are large particles viruses, somehow spherical, with spikes like a surface projection [33]. The particles have a diameter of around 125 nm. The envelope diameter is 85 nm and the spikes are 20 nm long, now it is found that the spikes of SARS-CoV-2 are longer which increased its pathogenicity.

The structure of the viral envelope as any membrane consisted of a lipid bilayer and a various number of structural proteins, these are membrane (M), envelope (E), and spike (S) [33] in a ratio of E:S:M 1: 20:300 [34]. The average number of spikes on the particle is around 74 [35]. However, SARS-CoV-2 has other short projection of a proteinous structure called hemagglutinin esterase (HE) [14].

The spikes are folded as homotrimers and recognized as two subunits S1 comprised the head structure and has the receptor-binding domains (RBD) which have the signal peptide and S2 is the stem of the spike consist of heptad repeat region (HR1 and HR2) and putative fusion peptide (F). Also, there are the transmembrane domain and endo-domain. All help on activation to facilitate fusion by, these subunits and are important for pathogenesis and maintain envelope integrity [36].

Finally, the nucleocapsid consists of nucleic acid (positive-sense single-stranded RNA genome) folded on multiple copies of protein (nucleocapsid, N). The organization is in a continuous bead-on-a string type conformation [36]. All those structures are important for the protection of the virus when it is outside host cells [37].



Figure 2: Comparison of Structure s of spike proteins and their organization in SARS-CoV, HCoV-229E and TGEV viruses.

Virus Classification

Realm: Riboviria

Kingdom: Orthornavirae

Phylum: Pisuiricota

Class: Pisoniviicetes

Order: Nidovirale

Family: Coronaviridae

Subfamily: Orthocornavirinae

Genera	Synonyms
Alphacoronavirus	Coronavirinae
Betacoronavirus	-
Gammacoronavirus	-
Deltacoronavirus	-

Genome Organization

Coronaviruses belong to the group of RNA viruses, its genome consist of a positive–sense, single-stranded RNA in a size range of 26 to 31 kilobases [20]. Morphologically and genetically, it is considered as the largest among all RNA viruses. Like the mRNA of eukaryotes, its RNA has a 5′ methylated cap and a 3′ polyadenylated tail [38].

The sequence of the coronavirus genome is in the following order; started with 5′-leader-UTR-then replicate/transcriptase-spike (S)-envelope (E)-membrane (M)-nucleocapsid (N) finally with-3′UTR-poly (A) tail. It contains several overlapped open reading frames, the first was 1a and 1b which was found in the first two-thirds of the genome and encode the replicase-transcriptase polyprotein (pp1ab) which is then self-cleaved producing 16 nonstructural proteins (nsp1-nsp16) [38]. That, other reading frames encoded the major structural proteins that are: spike, envelope, membrane, and nucleocapsid [39]. Then between these reading frames interspersed other reading frames encoded for the accessory proteins. Accessory proteins vary in number; however, their functions are unique among members of coronaviruses [38].

Organization of 5′-leader-UTR and 3′UTR-poly (A) tail:



Figure 3: The organization of 5′ UTR and 3′ UTR and coding region of COVID-19, SARS-CoV, and MERS-CoV viruses.

The 5′UTR and 3′UTR are two untranslated regions, they are unusual in composition and structure, the genome started with the 5′UTR and ended with 3′UTR. Functionally, they are responsible for viral replication, transcription, and packaging. They may have some role in controlling inter- and intra-molecular interactions. Especially that related to RNA-RNA interactions and binding of viral and cellular proteins.

As shown in (Figure 3), from the beginning at 5′end, the first reading frame is Pb1ab then the code for structural proteins with a size of 29844bp which comprise (7096aa), 29751bp which translated to (7073aa), and 30119bp which is (7078) in SARS-CoV-2, SARS-CoV; and MERS-CoV, respectively. The difference also found among these viruses in the spike protein which is located at 3′ end that is, translated as a polypeptide of 1273aa, 21493aa, and 1270aa in SARS-CoV-2, SARS-CoV, and MERS-CoV, respectively. The similarity was low (79%) between SARS-CoV-2 and SARS-CoV and MERS-CoV is (50%). Accordingly, that reflects the difference in all structural proteins among these viruses [38]. The 5′UTR and 3′UTR folded in a secondary structure in a hairpin form which is unusual as shown in (Figure 4).



Figure 4: The structure of 5' UTR and 3′UTR in SARS-CoV-2.

The Life Cycles



Figure 5: Schematic representation of SARS-CoV-2 life cycle.

Viral Attachment and Entry

Infection of the host cell normally begin when a viral particle reach to epithelial cells belong to the human pulmonary system (epithelial cells of bronchi) and started when the viral spike attached to the cell receptor, by chance, the receptor of angiotensin-converting enzyme-2 (ACE2) is complementary in shape to the spike shape which allows successful attachment to occur. Then, a protease (TMPRSS2) of the host cleaves and help the vision to pass through the membrane. This allows activation of the receptor-attached spike protein. Successful infections depend on the availability of protease as well as cleavage and activation which allows entering by either a mechanism of transport called endocytosis or direct fusion of the viral envelope which is composed of a lipid bilayer with that identical on of the host cell [40].



Figure 6: Viral attachment to receptors.

The new outbreak variant SARS-CoV-2 cause COVID-19 to follow the same mechanism of entry with increased aggression, virulence, and transmission due to its longer spike (S2 protein increased in length) due to mutation (insertion of the genomic fragment) or recombination event [11]. After successful entry to the host cell, the virus particle is uncoated, and its RNA genome strip in the cell cytoplasm [11]. The RNA genome has a 5′ methylated cap and a 3′ polyadenylated tail which is important for translation events to allow RNA of the virus to attach to the host cell's ribosome for translation [38]. The host ribosome is captured by virion genomic regulatory genes and forced to translates the initial overlapping open reading frame of the virus genome and forms a long polyprotein. The polyprotein has to be separated by its proteases which cleave the polyprotein into multiple nonstructural proteins [38].

RNA Replication and Transcription

Once successful entry occurs, replication of the viral genome occurs. This is a special type of replication if the virus genome is RNA. Accordingly, a special type of replication complex formed that is, the replicase-transcriptase complex (RTC), which is organized to replicate the viral genome. The RNA dependent RNA polymerase (RdRp), the main component of the complex, directly mediates the synthesis of negative-sense genomic RNA from the positive-sense genomic RNA. This is followed by the replication of positive-sense genomic RNA from the negative-sense genomic RNA [38].

Figure 7: Replicase-transcriptase complex components.

Several non-structural proteins coalesce around and complexes to form a big multi-protein structure called replicase-transcriptase complex (RTC). This is unusual machinery to propagate genomic RNA producing genomes of the progeny. The main protein in the complex is the enzyme RNA-dependent RNA polymerase (RdRp), the enzyme capable of replication and transcription of RNA from RNA strand as one process. However, another number of non-structural proteins assist in completing the process of either replication or transcription.

Proofreading for fidelity is also required, an exoribonuclease enzyme is a nonstructural protein, provides that fidelity by doing proofreading function if the RdRp goes not have exonuclease activity and unable to proofreading.

Transcription

The second function of RNA-dependent RNA-polymerases to transcribe several structural and nonstructural proteins required by the virion to complete the required components of producing a new genome for progenies. RdRp directly mediates the synthesis of negative-sense subgenomic RNA molecules from the positive-sense genomic RNA. Then, this process is followed by a transcription of the negative strand subgenomic RNA molecules [38]. Accordingly, the subgenomic mRNAs form several nested sets" of RNA which have common start 5'-head and partially duplicate 3'-end [41].

Release of Viral Progeny Particles

After replication completion, with the synthesis of all genome components of the initial overlapping frame, the replicated positive-sense RNA molecules comprise all the genomes of the new progenies, now translation of the mRNA by the host's ribosomes into the structural proteins and several accessory proteins are started [41]. However, the Endoplasmic reticulum is the place of RNA translation, the products of translation, that are the viral structural proteins S, E, and M as well as the secretory pathway components into the Golgi intermediate compartment. Then, M protein starts to make most interactions between protein molecules to the assembly of viruses following its binding to the nucleocapsid. Progeny viruses are then released from the host cell by exocytosis through secretory vesicles. Once released the viruses can infect other host cells [42].

Genetic Changes

Genetic changes of the virus could have occurred through two main processes that are gene mutation and recombination then followed by a selection of successful genotype. These two processes cause the emergence of new phenotypes with improved capabilities and that allows successful outbreak by increase virulence and transmission. In 2019 with the new outbreak and emergence of new variants in Iceland, UK, it was found that more than [37] mutations of SARS-CoV-2 among people with the dead body in the country along with other seven infections came from people attended from outside. Later, more than (200) other mutations were registered by UCL Genetics Institute, during the emergence of new variants. Accordingly, scientists discovered that a small genetic change (gene mutation) occurs.

During analyzing a swab of COVID-19 patients. Later, a (648) new cases have been detected [11]. Interestingly, the [40] specific variants fall into three clusters with either deletions or insertion in their genome. The other (200) variants were continued to be traced as that can mutate reasonably violently. Two separate types of novel strain one more aggressive than the other were detected. Over time, the new virus will likely become more contagious, but the variants that cause severe symptoms may die out [42]. Numbers of deletions were observed during tracing the genome of many newly developed variants.

Random mutations in the SARS-CoV-2 pathogen's genome help researchers track the spread and transmission of COVID-19, the disease it causes. Later, Genetic analysis revealed that three deletions in the genome of SARS-CoV-2 isolated from Japan (Aichi), USA (Wisconsin), and Australia (Victoria) as shown I (Figure 8) were developed. A deletion mutation in the open reading frame (1ab) of the polyprotein (one deletion of three nucleotides and the other of twenty-four nucleotides). The other deletion of ten nucleotides in the 3′ end of the genome was also observed [56].



Figure 8: Mutations in the genome of SARS-CoV-2.

The study, led by the UCL Genetics Institute, identified new 200 genetic mutations in the virus, highlighting how this virus developed mechanisms for adaption and evolved to infect human hosts [42]. Researchers found that a large proportion of the global genetic changes of SARS-CoV-2 is found in all hardest-hit countries, suggesting extensive global transmission from early in the epidemic [42].To defeating viruses is that in the development of a vaccine or working efforts on parts of the virus that are less likely to mutate are a challenging affords. In the meantime, we have a better chance of developing drugs that will be effective in the long run [42].

Recombination

The second mechanism for genetic changer is recombination, Replicase transcriptase complex help in facilitates recombination. It requires two complementary strands to come close that is when at least two viral genomes are present in the same infected cell, then some genes jump from one host to another, producing one stand with deletion and the other with insertion. The sequence of the frame in these two genomic products will be changed, accordingly, the sequence of amino acids in the product will change as a result [41].

Recombination among RNA molecules seems to be a major mechanism for variability in the genome of coronaviruses and it is a driving force for introducing new virulence genes and help coronavirus in transmission. The capability of a coronavirus species to jump from animal to human and move from one human host to another and their genetic instability, infrequently, it could help in determining the emergence of novel coronaviruses [41]. However, the exact mechanism of recombination in coronaviruses is unclear, but likely, it is activated during replication and may involve template switching [41].

Conclusion

At present, there are no specific drugs or vaccines to control COVID-19. It became worse as long as, the virus is unstable and in continuous changes either by mutation or recombination producing high virulent progenies capable of the high rate of transmission and spread. As well as its pandemics increase its pathogenicity and dander during disease control. Accordingly, it is important to study the basis of replication, structure, genetic changes either by mutation or recombination to control the disease by discovering a way to special treatment or prevention. Efforts have had been made to provide medicines and vaccines for COVID-19 control. Studying the species' molecular details helps in achieving treatment goals.

References

1. Ksiazek TG, Erdman D, Goldsmith C, Zaki SR, Peret T, et al. (2003) SW Group A novel coronavirus

associated with severe acute respiratory syndrome. N Engl J Med 348: 1953-1966. https://doi.org/10.1056/NEJMoa030781

2. Li Q, Guan X, Wu P, Wang X, Zhou L, et.al. (2020) Early transmission dynamics in Wuhan, China, of Novel Coronavirus-infected pneumonia. N Engl J Med 382: 1199-1207. https://doi.org/10.1056/NEJMoa2001316

3. Zheng M, Gao Y, Wang G, Song G, Liu S, et al. (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17: 533-535. https://doi.org/10.1038/s41423-020-0402-2

4. Zhang J, Litvinova M, Wang W, Wang Y, Deng X, et.al. (2020) Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infect Dis 20: 793-802. https://doi.org/10.1016/S1473-3099(20)30230-9

5. Huang C, Wang Y, Li X, Ren L, Zhao J, et.al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5

6. Shi H, Han X, Jiang N, Cao Y, Alwalid O, et al. (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 20: 425-434. https://doi.org/10.1016/S1473-3099(20)30086-4

7. Zhou F, Yu T, Du R, Fan G, Liu Y, et.al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3

8. Cao B, Wang Y, Wen D, Liu W, Wang J, et al. (2020) A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382: 1787-1799. https://doi.org/10.1056/NEJMoa2001282.

9. Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, et.al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

10. Tung Ph (2020) Genetic diversity and evolution of SARS-CoV-2. Infect Gen Evolut 81: 104260. https://doi.org/10.1016/j.meegid.2020.104260

11. Definition of Coronavirus (2020) Merriam-Webster. Merriam-Webster.

12. Tyrrell DA, Fielder M. (2020) Cold Wars: The Fight Against the Common Cold. Oxford University Press 96.

13. Sturman LS, Holmes KV (1983) Lauffer MA, Maramorosch K (eds.) "The molecular biology of coronaviruses". Adv Virus Res 28: 35-112. https://doi.org/10.1016/S0065-3527(08)60721-6

14. McIntosh K (1974) Coronaviruses: A Comparative Review. Curr Topics Microbiol Immunol. Berlin, Heidelberg: Springer. 63: 85-129. https://doi.org/10.1007/978-3-642-65775-7_3

15. Il étaitunefois les coronavirus (2020) RéalitésBiomédicales.

16. Kahn JS, McIntosh K (2005) History and recent advances in coronavirus discovery. Pediat Infect Dis J 24: S223-7. https://doi.org/10.1097/01.inf.0000188166.17324.60

17. Monto AS (1984) Coronaviruses. In Evans AS (eds.) Viral Infections of Humans. Viral Infect Humans Epidemiology and Control Springer, United States. https://doi.org/10.1007/978-1-4613-0705-1_7

18. Tyrrell DA, Bynoe ML (1995) Cultivation of a Novel Type of Common-Cold Virus in Organ Cultures. Brit Med J 1: 1467-70. https://dx.doi.org/10.1136/bmj.1.5448.1467

19. Tyrrell DA, Fielder M (2002) Cold Wars: The Fight Against the Common Cold. Oxford University Press pp. 93-95.

20. Knapp A (2020) The Secret History of The First Coronavirus. Forbes.

21. Yousif NG (2014) Fibronectin promotes migration and invasion of ovarian cancer cells through up regulation of FAK–PI 3 K/A kt pathway. Cell Biol Int 38: 85-91. https://doi.org/10.1002/cbin.10184

22. McIntosh K, Dees JH, Becker WB, Chanock RM (1967) Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A 57: 933-939. https://dx.doi.org/10.1073/pnas.57.4.933

23. Myint SH (1995) Human Coronavirus Infections. In Siddell SG (ed.). The Coronaviridae. The Viruses. Springer US. pp: 389-401.

24. Corman VM, Jores J, Meyer B, Younan M, Liljander A, et al. (2014) Antibodies against MERS Coronavirus in Dromedary Camels, Kenya, 1992–2013. Emerg Infect Dis 20: 1319-22. https://dx.doi.org/10.3201/eid2008.140596

25. Keller SA, Bolan GB (2016) Herpes simplex in leukemic child: an unusual presentation. Am J BioMed 4: 534-542. https://doi.org/10.18081/2333-5106/016-12/534-542

26. Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. In Maier HJ, Bickerton E, Britton P (eds.) Coronaviruses. Methods in Molecular Biology. 1282. Springer, United States. http://doi.org/10.1007/978-1-4939-2438-7_1

27. Lai MM, Cavanagh D (2008) The Molecular biology of coronaviruses. Adv Virus Res 48:1-100. https://dx.doi.org/10.1016/S0065-3527(08)60286-9

28. Cavanagh D, Mawditt K, Sharma M, Drury SE, Ainsworth HL, et al. (2001) Detection of a coronavirus from turkey poults in Europe genetically related to infectious bronchitis virus of chickens. Avian Pathol 30: 355-368. https://doi.org/10.1080/03079450120066368

29. Neuman BW, Gabriella K, Kunding AH, Bhella D, Baksh MF, et al. (2011) A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol 174: 11-22. https://doi.org/10.1016/j.jsb.2010.11.021

30. Chang CK, Hou MH, Chang CF, Hsiao CD, Huang TH (2014) The SARS coronavirus nucleocapsid protein – Forms and functions. Antiviral Res 103: 39-50. https://doi.org/10.1016/j.antiviral.2013.12.009

31. Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, et al. (2003) Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 331: 991-1004. https://doi.org/10.1016/S0022-2836(03)00865-9

32. Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S (2013) Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral res 100: 605-614. https://doi.org/10.1016/j.antiviral.2013.09.028

33. Singer BS, Blinov SK (2014) The epidemiological characteristics of Ebola Virus Disease. Am J BioMed 2: 1095-1109.

34. Susan P (2020) Family Coronaviridae. Viruses, Academic Press, United States.

35. Yousif NG, Al-Amran FG, Hadi N, Lee J, Adrienne J (2013) Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine 61: 223-227. https://doi.org/10.1016/j.cyto.2012.09.022

36. Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17: 181-192. https://doi.org/10.1038/s41579-018-0118-9

37. Decaro N, Tidona C, Darai GA (2011) Alphacoronavirus. The Springer Index of Viruses, Springer, New York, United States. https://doi.org/10.1007/978-0-387-95919-1

38. Decaro N. Tidona C, Darai G (2011) Betacoronavirus. The Springer Index of Viruses, Springer, New York, United States. https://doi.org/10.1007/978-0-387-95919-1_57

39. Li W, Farzan M, Harrison SC (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309: 1864-1868. https://doi.org/10.1126/science.1116480

40. Navarro SB, Peiris BM (2014) Human papilloma virus (HPV) vaccine: Gardasil reactions. AJBM 2: 146-155.

41. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, et al. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181: 271-280. https://doi.org/10.1016/j.cell.2020.02.052

42. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, et al. (2020) The origin, transmission, and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 7: 1-10. https://doi.org/10.1186/s40779-020-00240-0

Chapter -4

Immunological Aspects Regarding COVID-19

Introduction

The disease COVID-19 is caused by the novel coronavirus SARS-CoV2, and now is a pandemic putting the lives of millions of people under threat. The virus can proliferate, unhindered, in tissues primarily infected, because protective immunity is not present in man and the virus can escape innate immune responses. The release of intracellular components and virus particles to the extracellular compartment subsequently follows cell death, leading to the recruitment of immune cells, the buildup of immune complexes, and accompanying damage. Massive inflammatory reactions later in the disease course will follow the recruitment of uninfected immune cells and infection of monocytes and macrophages.

Cytokine storm syndrome and ARDS and will follow the uncontrolled production of pro-inflammatory mediators. Available treatment options at present are the immune-modulating treatments and antiviral agents; however, these agents are under the trails. The key element in predicting the outcome in patients with COVID-19 is to understand the immune evasion strategies of SARS-CoV2 and the resulting delayed massive immune response. This understanding may provide help to identify biomarkers that predict outcomes.

Coronaviruses were used to be labeled as causes of mild respiratory and GIT infections; however, when the SARS outbreak in 2002 was attributed to the coronavirus, the potential of these viruses for the epidemic spread and substantial pathogenesis become well known among healthcare providers globally [1]. High case rates in humans in the last three decades have been caused by three principal beta-corona viruses, Severe Acute Respiratory Syndrome (SARS)-CoV, Middle East Respiratory Syndrome (MERS)-CoV, and SARS-CoV2 [2-4]. Till the moment of writing the current review article, SARS-CoV2 has infected approximately three million people worldwide and has caused the death of around 200,000 people. The current review is focused basically on the immune aspects in association with COVID-19.

Virus Structure

Coronaviruses are with a wide host range and are highly prevalent animal pathogens. Generally, the known coronavirus species are thousands [5,6]. The recognized human coronaviruses are 7 in number. These are Human CoVs E229, NL63, OC43, HKU1, and all novel CoVs (including SARS-CoV2) [7].

"Coronaviruses (CoVs) are large enveloped viruses with a single-stranded, non-segmented, positive-sense RNA genome that spans approximately 30 kilobases, making it the largest known genome of any RNA virus" [8]. CoVs readily evolve by mutation and homologous and non-homologous recombination, because of being RNA viruses. This expands its host range [9,10]. These viruses are regarded as zoonoses. "Novel coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV2 are comparatively poorly adapted to humans, which affects their pathogenic potential" [6,11].

The viruses are spherical and the most characteristic feature is the "spikes", prominent club-like projections on their surface. The virus membrane contains four structural components, the spike (S), envelope (E), membrane (M), and nucleocapsid (N) protein [8] (Figure 1).



Figure 1: Structure of SARS-CoV2.

The spike protein (S) facilitates binding to the trans-membrane ACE2 host receptor; the envelope (E) protein together with the membrane (M) protein form the viral envelope and determine its shape; the hemagglutinin esterase (HE) protein may resemble another cell entry mechanism of novel CoVs; the Nucleocapsid (N) protein inbound to the RNA genome of the virus to form the nucleocapsid [7].

NL63, SARS-CoV, and SARS-CoV2 all use the transmembrane angiotensin-converting enzyme (ACE2) as a host receptor, whereas MERS CoV utilizes dipeptidyl peptidase-4 (DPP4) [12]. Both receptors are transmembrane ectoenzymes that are highly conserved among mammals, thus facilitating the interspecies transfer. However, their enzymatic activity in itself is not necessary for successful binding and fusion [13-15].

The binding affinity of the S protein of SARS-CoV2 and ACE2 is high. High sequence and conformational conservation of the S protein observed across SARS-CoV2 and SARS-CoV allows for some level of cross-neutralization of the two viruses in vitro [16,17].

Hemagglutinin residues enhance binding by allowing interactions with sialic acid residues on host cell surfaces. Beta coronaviruses feature yet another structural protein, hemagglutinin-esterase (HE) which binds sialic acid on cell surfaces [18] (Figure 1). This may enhance the virus's ability to bind and invade host cell surfaces and may constitute a virulence factor in novel hCoVs.

Immunological Aspects

80% of SARS-Cov2 are either asymptomatic or results in mild respiratory illness, but 20% of cases are severe may be critical [19,20].

Mechanisms of Infection and Immune Evasion

While data on SARS-CoV2 are still sparse, parallels with SARS-CoV and MERS-CoV may (for now) allow extrapolation of knowledge to understand how SARS-CoV2 escapes the host's immune response. Notably, SARS-CoV2 shares almost 80% RNA sequence homology with SARS-CoV, and 50% with MERS-CoV (21), with SARS-CoV2 exhibiting additional genomic regions when compared to SARS-CoV. In particular, the viral spike protein, which binds to the host cell receptor, is 20-30 amino acids longer than SARS-CoV, and other closely related coronaviruses [21].

Thus, it is possible, even likely, that SARS-CoV2 uses similar immune evasion strategies to other coronaviruses, but additional as yet undiscovered mechanisms may also be utilized by SARS-CoV2 [22]. As mentioned above, SARS-CoV and SARS-CoV2 both use ACE2 as their host cell receptor to establish infection (Figure 2A) [23]. ACE2 is expressed in almost all organs in the body. ACE2 is highly expressed on surfactant producing type 2 alveolar cells, and on ciliated and goblet cells in the airways; these cells likely provide a portal of entry for the virus in humans [24-26].

High ACE2 expression is also observed in the intestinal epithelium [27]. Furthermore, ACE2 is expressed on cardiac cells and vascular endothelia, which may explain cardiovascular complications in some patients [28]. For SARS-CoV, infection of immune cells including monocytes/macrophages and T cells has been observed. It is not clear to date whether and to what extent SARS-CoV-2 can also infect these cell types. ACE2 is also, but at lower levels and not ubiquitously, expressed on monocytes and macrophages, so this may also provide an entry mechanism into immune cells for SARS-CoV-2. However, other receptors and/or phagocytosis of virus-containing immune complexes may also be involved (Figure 1B) [22,29,30].

The host response and clearance of viral infections heavily rely on type I interferon (T1IFN) expression [31]. Expression of T1IFN and down-stream signals modulate cell responses and reprogram cells into an "anti-viral state", subsequently promoting infection control and pathogen clearance [32]. As a first step, immune cells sense viral infection through the identification of virus-derived pattern associated molecular patterns (PAMPs), such as viral RNA. These bind to and activate pattern recognition receptors (PRRs) in/on immune cells and result in immune cell activation (Figure 2).

RNAs viruses, such as SARS-CoV, SARS-CoV2, and MERS-CoV are detected by endosomal RNA PRRs, including Toll-like receptors (TLR-)3 and 7 and/or cytoplasmic RNA sensors, namely retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) (Figure 2). Usually, TLR3/7 activation results in nuclear translocation of the transcription factors NFκB and IRF3, while RIG-1/MDA5 activation results in the activation of IRF3.



Figure 2: Immune evasion strategies of SARS-CoV2. A) SARS-CoV2 infects airway epithelial cells through

interactions with the transmembrane enzyme ACE2 (a). While RNA viruses usually activate TLR3 and/or 7 in endosomes (b) and cytosolic RNA sensors RIG-I and MDA-5 (c), SARS-COV2 effectively suppresses the activation of TNF receptor-associated factors (TRAF) 3 and 6, thereby limiting activation of the transcription factors NFκB and IRF3 and 7, thereby suppressing early pro-inflammatory responses through type I interferons (IFN) and pro-inflammatory effector cytokines IL-1, IL-6, and TNF-α (red symbols). Furthermore, novel CoVs inhibit the activation of STAT transcription factors (d) in response to type I IFN receptor activation, which further limits antiviral response mechanisms. Altogether, this prohibits virus containment through the activation of anti-viral programs and the recruitment of immune cells. B) Tissue monocytes/macrophages express ACE2 to a significantly lower extent, making infection through this route less likely (a). However, immune complexes consisting of ineffective antibodies against e.g. seasonal CoVs and virus particles may be taken up by macrophages through Fcγ receptors resulting in their infection (b). In a process referred to as antibody directed enhancement (ADE), virions inhibit type I IFN signalling in infected macrophages while allowing pro-inflammatory IL-1, IL-6, and TNF-α expression, which may contribute to hyperinflammation and cytokine storm syndrome (c,d). Inhibited type 1 IFN signalling suppresses anti-viral programs, while increased IL-1, IL-6, and TNF-α expression auto-amplifies itself through positive feedback loops (f) [7].

In turn, these triggers increased expression of T1IFN (through IRF3) and other innate pro-inflammatory cytokines (IL-1, IL-6, TNF-α through NFκB) [22,33]. In this context, T1IFN and other innate pro-inflammatory cytokines promote their expression through auto-amplification: T1IFN activate the IFN-α receptor complex (IFNAR) which results in the phosphorylation/activation of STAT family transcription factors 1 and 2 (Figure 2), while IL-1, IL-6, and TNF receptor activation feed into pro-inflammatory cytokine expression though the transcription factor NFκB (Figure 2) [32-34]. Activation and priming of innate and adaptive immune responses should result in pathogen clearance and recovery.

However, in a proportion of infected individuals, SARS-CoV, MERS-CoV and likely SARS-CoV2 evade immune system recognition through suppression of these mechanisms, a phenomenon associated with more severe disease and poorer prognosis [35-37] (Figure 2, red symbols). SARS-CoV has been shown to alter ubiquitination and degradation of RNA sensors (RIG-I and MDA5).

It inhibits activation of mitochondrial antiviral-signaling protein (MAVS), which are essential for the activation and nuclear translocation of IRF3 in response to cytoplasmic RNA sensor activation. Furthermore, SARS-CoV, and likely SARS-CoV2, inhibit the TNF receptor-associated factors (TRAF) 3 and 6, which are central for the induction of IRF-3/7 in response to TLR3/7 and/or RIG-I and MDA-5 ligation as well as NFκBsignaling pathways (which are usually activated in response to TLR3/7 ligation or cytokine receptor signaling) [36]. Lastly, novel coronaviruses can counteract T1IFN signaling through inhibition of STAT family transcription factor phosphorylation [33]. Taken together, suppression of innate immune mechanisms in infected epithelial cells and, to some extent, infected monocytes/macrophages allow novel coronaviruses to proliferate without triggering the innate anti-viral response machinery of these cells.

However, at a later stage, infected cells undergo cell death and release virus particles together with intracellular components that trigger innate inflammatory mechanisms through their recognition by PRRs in/on innate immune cells. As a result of this innate immune activation and the resultant expression of pro-inflammatory cytokines (including IL-1β, IL-6, TNF-α, etc.), adaptive immune cells become involved in the host's defense against viral infections. T lymphocytes play a central role in this anti-viral response, including CD4+ T cell derived cytokines, CD8+ T cell mediated cytotoxicity, and B cell activation resulting in antibody production. Novel coronaviruses may also (partially) escape these mechanisms through the induction of T cell apoptosis [38]. However, lymphocytes may also become depleted due to the expression of pro-inflammatory cytokines by (not infected) innate immune cells that become recruitedto the lungs and trigger hyper-inflammation, seen during the development of a "cytokine storm" [39].

Hyperinflammation and Cytokine Storm

While symptoms of COVID-19 disease maybe (sometimes only slightly) milder in comparison to infections with SARS-CoV or MERS-CoV, several key pathogen-associated and clinical features of the disease are similar and we can extrapolate knowledge from what is already known about the pathophysiology of SARS and MERS [7].

In COVID-19, as in SARS or MERS, several key findings were associated with poor outcomes in cohort studies, and suggest hyper-inflammation may be linked to more severe disease. Three early studies from Wuhan linked cytopenia and/or significantly elevated inflammatory parameters with severe disease and unfavorable outcomes. One study, involving 99 patients reported neutrophilia (38%), lymphopenia (35%), and increased systemic inflammatory proteins (IL-6 in 52%, and CRP in 84%) as common symptoms in COVID-19 disease [18]. Another study involving 41 individuals, linked severe disease culminating in ICU admission and mortality, with neutrophilia and lymphopenia [4]. The third study reported significant leukopenia (11.8%), lymphopenia (77.6%), thrombopenia (41.2%), anemia (48.2%), hypofibrinogenemia (22.4%), and hypo-albuminemia (78.8%) in a cohort of 85 patients who died from COVID-19 [30,40].

These observations are in line with findings in severe or lethal cases of SARS and MERS, in which increased numbers of neutrophils and monocytes/macrophages are present in the airways [30,41]. Other groups reported severe clinical phenotypes and ICU dependency of patients to be associated with increased plasma levels of innate chemokines, specifically C-X-C motif chemokine 10 (CXCL10)/ Interferon gamma-induced protein 10 (IP-10), chemokine (C-C motif) ligand 2 (CCL2)/monocyte chemoattractant protein 1 (MCP-1), Macrophage Inflammatory Protein (MIP-)1A/CCL3, and the pro-inflammatory cytokine TNF-α [2]. This, indeed, is similar to the situation reported in SARS and MERS in which uncontrolled inflammation centrally contributes to poor outcomes [42-44].Though seemingly contradictory to mechanisms of immune evasion discussed above, enhanced innate immune activation, including increased T1IFN, IL-1β, IL-6, and TNF-α expression centrally contributes to morbidity and mortality in COVID-19, MERS and SARS. One possible explanation is the induction of endothelial and vascular cell damage and cell death because of viral replication. Virus-induced inflammatory cell death, including necrosis or proptosis, result in pro-inflammatory cytokine expression, (uninfected) immune cell recruitment and activation [45]. Mice infected with SARS-CoV exhibit excessive T1IFN secretion from myeloid cells in infected tissues. Indeed, immune evasion through the suppression of anti-viral responses and T1IFN expression in respiratory epithelia results in high viral loads [35]. From this, it is hypothesized that (not infected) monocytes/macrophages and neutrophils recruited to the site of infection exhibit strong and poorly controlled inflammatory responses, resulting in tissue damage and systemic inflammation, both of which contribute to morbidity and mortality [28] (Figure 3).

Another factor thought to contribute to organ damage and poor outcomes are the early production of neutralizing antibodies against coronaviruses. Antibody-dependent enhancement (ADE) is a phenomenon shown to contribute to damage accrual during viral infections. It has been shown to promote cellular uptake of virus particles bound in immune complexes, through their binding to Fcγ receptors (FcγR). This may contribute to the aforementioned persistent viral replication in immune cells (including newly infected antigen-presenting cells), but also immune complex mediated inflammatory responses (Figure 2 to Figure 4), that contribute to tissue and organ damage, including acute respiratory distress syndrome (ARDS) [46-48]. Indeed, a subset of COVID-19 patients reportedly developsvasculitic lesions, blood vessel occlusion and infarctions. Histopathologic reports from tissue sections suggest features associated with immune complex mediated vasculitis, including infiltration of monocytes and lymphocytes within and around blood vessels, wall thickening, and focal hemorrhage [28,49-51].



Figure 3: Inflammatory response through monocytes macrophages. Uninfected monocytes/macrophages from the blood stream invade the lungs where they detect virus particles and/or cytoplasmic and nuclear components. Within immune complexes, these particles are taken up into the cell (a) where they are presented to TLRs, activating NFκB and/or IRF dependent pro-inflammatory pathways (b,c). As a result, uninfected monocytes/macrophages produce significant amounts of pro-inflammatory cytokines (d,e) which recruit additional innate and adaptive immune cells and cause additional tissue damage [7].



Figure 4: Inflammatory mechanisms in immune complex vasculitis [7].

As is true for several systemic autoimmune and inflammatory conditions, uncontrolled activation of

immune responses is (likely) not limited to the innate mechanisms. As a result of pro-inflammatory cytokine expression and the presence of nuclear antigens (from cell and tissue damage), adaptive immune cells may become activated and trigger a "second wave" of inflammation (potentially in those patients who deteriorate after 7-10 days of infection). Indeed, adaptive immune cells, namely T lymphocytes, which are observed in lung tissue sections of COVID-19 patients with ARDS and/or cytokine storm, may drive inflammation at later disease stages. Similar mechanisms have been reported in influenza and other viral infections. Overall, severely ill COVID-19 patients experiencing cytokine storm exhibit lymphopenia and sometimes atrophy of the lymphatic tissues, namely lymph nodes and spleen [51]. This is in line with reports in primary and secondary forms of Hemophagocytic lymphohistiocytosis (HLH) and associated cytokine storm, which results in inflammatory cell death and hypo-cellularity of lymphatic organs [50].

Herd Immunity: Understanding COVID-19

Basic Concepts of Herd Immunity

Acquired immunity is established at the level of the individual, either through natural infection with a pathogen or through immunization with a vaccine. Herd immunity stems from the effects of individual immunity scaled to the level of the population. It refers to the indirect protection from infection conferred to susceptible individuals when a sufficiently large proportion of immune individuals exist in a population. This population-level effect is often considered in the context of vaccination programs, which aim to establish herd immunity so that those who cannot be vaccinated, including the noticeably young and immunocompromised, are still protected against disease. Depending on the prevalence of existing immunity to a pathogen in a population, the introduction of an infected individual will lead to different outcomes (Figure 5).



Figure 5: Herd Immunity. (A) SIR (susceptible, infectious, recovered) model for a completely immunizing

infection with an R0 = 4. The model assumes a closed population in which no people leave and no new cases are introduced. Following the introduction of a single infected individual, the proportion of infected individuals (red line) increases rapidly until reaching its peak, which corresponds to the herd immunity threshold. After this point, newly infected individuals infect less than one susceptible individual, as a sufficient proportion of the population has become resistant, preventing further spread of the pathogen (orange line).

(B) Schematic depiction of the disease propagation dynamics when one infected individual is introduced into a completely susceptible population (top panel) versus a situation in which an infected individual is introduced into a population that has reached the herd immunity threshold (bottom panel). In the naive population, an outbreak quickly emerges, whereas under the scenario of herd immunity, the virus fails to spread and persist in the population.

In a completely native population, a pathogen will propagate through susceptible hosts in an unchecked manner following the effective exposure of susceptible hosts to infected individuals. However, if a fraction of the population has immunity to that same pathogen, the likelihood of effective contact between infected and susceptible hosts is reduced, since many hosts are immune and, therefore, cannot transmit the pathogen.

If the fraction of susceptible individuals in a population is too few, then the pathogen cannot successfully spread, and its prevalence will decline. The point at which the proportion of susceptible individuals falls below the threshold needed for transmission is known as the herd immunity threshold [7]. Above this level of immunity, herd immunity begins to take effect, and susceptible individuals benefit from indirect protection from infection (Figure 5B).

Under the simplest model, the herd immunity threshold depends on a single parameter known as R0 or the basic reproduction number. R0 refers to the average number of secondary infections caused by a single infectious individual introduced into a completely susceptible population. If we consider a hypothetical pathogen with an R0 of 4, this means that, on average, one infected host will infect four others during the infectious period, assuming no immunity exists in the population. Mathematically, the herd immunity threshold is defined by 1-1/R0 (e.g., if R0 = 4, the corresponding herd immunity threshold is 0.75) [5]. Therefore, the more communicable a pathogen, the greater it's associated R0, and the greater the proportion of the population that must be immune to block sustained transmission.

A similar parameter important for understanding population-level immunity is the effective reproduction number (Re or Rt). Re is defined as the average number of secondary cases generated by a single index case over an infectious period in a partially immune population [6]. Unlike R0, Re does not assume a completely susceptible population and, consequently, will vary depending on a population's current immune state, which will change dynamically as an outbreak event or vaccination campaign unfolds. Ultimately, the goal of vaccination programs is to bring the value of Re below 1. This occurs when the proportion of the population with immunity exceeds the herd immunity threshold. At this point, pathogen spread cannot be maintained, so there is a decline in the number of infected individuals within the population.

Herd Immunity and SARS-CoV-2

The ongoing SARS-CoV-2 pandemic has caused over 3.5 million clinically confirmed cases of COVID-19 and has claimed more than 250,000 lives worldwide (as of May 4, 2020). Numerous clinical trials to evaluate novel vaccine candidates and drug repurposing strategies for the prevention and treatment of SARS-CoV-2 infection are currently ongoing. However, it is unknown whether these trials will produce effective interventions, and it is unclear how long these studies will take to establish efficacy and safety, although an optimistic estimate for any vaccine trial is at least 12-18 months. In the absence of a vaccine, building up SARS-CoV-2 herd immunity through natural infection is theoretically possible. However, there is no straightforward, ethical path to reach this goal, as the societal consequences of achieving it are devastating.

Since the onset of SARS-CoV-2 spread, various studies have estimated the basic reproductive number (R0) of the virus to be in the range of 2 to 6. From an initial cohort of 425 confirmed cases in Wuhan, China, an R0 of approximately 2.2 was estimated, meaning that, on average, each infected individual gives rise to 2.2 other infections [18]. More recent estimates place the R0 higher at 5.7, although many estimates fall within this range [8]. This variation reflects the difficulty of obtaining accurate R0 estimates in an ongoing

pandemic, and the current estimated SARS-CoV-2 R0 values likely do not indicate a complete picture of the transmission dynamics across all countries.

Assuming an R0 estimate of 3 for SARS-CoV-2, the herd immunity threshold is approximately 67%. This means that the incidence of infection will start to decline once the proportion of individuals with acquired immunity to SARS-CoV-2 in the population exceeds 0.67. As discussed above, this model relies on simplifying assumptions, such as homogeneous population mixing and uniform sterilizing immunity in recovered individuals across demographic groups, which are unlikely to hold. Nevertheless, this basic model can give us a rough idea of the number of individuals that would need to be infected to achieve herd immunity in the absence of a vaccine given an approximate herd immunity threshold and a country's population.

Consequences of Reaching the SARS-CoV-2 Herd Immunity Threshold in the Absence of a Vaccine

One important measure to evaluate the impact of SARS-CoV-2 spread is the overall case fatality rate (CFR). The CFR is the proportion of deaths attributed to a certain disease among all individuals diagnosed with that disease (i.e., cases) over a specified period. It is worth noting that there is still significant uncertainty in the CFR for COVID-19 due to variation in the testing capacity per country, selection bias for which individuals receive testing, and differences in how deaths are officially attributed to COVID-19. Further, CFR is also sensitive to variation in the underlying age structure and distribution of comorbidities among populations.

Consequently, CFRs may differ considerably over time and between countries. In the case of COVID-19, the initial estimate of the CFR in a small cohort of 41 individuals with laboratory-confirmed SARS-CoV-2 infection was high (15%) [9]. However, this number has markedly decreased as more data have become available. Using data from all laboratory-confirmed and clinically diagnosed cases from mainland China, Verity et al. obtained an estimated overall CFR of 1.38%, adjusted for censoring, under-ascertainment, and the underlying demography in China, and similar estimates have been obtained from other groups [19]. Like many other infectious diseases, a non-uniform COVID-19 CFR has been reported across age groups, with most deaths occurring among individuals 60 years old or greater.

The most relevant measure to evaluate the societal cost of achieving global SARS-CoV-2 herd immunity is the overall infection fatality rate (IFR). The IFR is defined as the proportion of deaths caused by a certain disease among all infected individuals. Because some cases will not be reported, especially among asymptomatic hosts or individuals with mild symptoms, the IFR will inherently be lower than the CFR. If we combine infection fatality data with an estimate of the number of individuals that need to develop immunity to reach the herd immunity threshold, we can project the expected number of deaths because of meeting this threshold.

Consequences of Reaching the SARS-CoV-2 Herd Immunity Threshold in the Absence of a Vaccine

One important measure to evaluate the impact of SARS-CoV-2 spread is the overall case fatality rate (CFR). The CFR is the proportion of deaths attributed to a certain disease among all individuals diagnosed with that disease (i.e., cases) over a specified period. It is worth noting that there is still significant uncertainty in the CFR for COVID-19 due to variation in the testing capacity per country, selection bias for which individuals receive testing, and differences in how deaths are officially attributed to COVID-19. Further, CFR is also sensitive to variation in the underlying age structure and distribution of comorbidities among populations.

Consequently, CFRs may differ considerably over time and between countries. In the case of COVID-19, the initial estimate of the CFR in a small cohort of 41 individuals with laboratory-confirmed SARS-CoV-2 infection was high (15%) [9]. However, this number has markedly decreased as more data have become available. Using data from all laboratory-confirmed and clinically diagnosed cases from mainland China, Verity et al. obtained an estimated overall CFR of 1.38%, adjusted for censoring, under-ascertainment, and

the underlying demography in China, and similar estimates have been obtained from other groups [19]. Like many other infectious diseases, a non-uniform COVID-19 CFR has been reported across age groups, with most deaths occurring among individuals 60 years old or greater.

The most relevant measure to evaluate the societal cost of achieving global SARS-CoV-2 herd immunity is the overall infection fatality rate (IFR). The IFR is defined as the proportion of deaths caused by a certain disease among all infected individuals. Because some cases will not be reported, especially among asymptomatic hosts or individuals with mild symptoms, the IFR will inherently be lower than the CFR. If we combine infection fatality data with an estimate of the number of individuals that need to develop immunity to reach the herd immunity threshold, we can project the expected number of deaths because of meeting this threshold.

Because of the uncertainty in the COVID-19 IFR, we use three different point estimates in our analysis: (1) an IFR of 0.2%, (2) an IFR of 0.6% that is in line with the IFR determined by Verity, and (3) an IFR of 1%. Assuming a uniform herd immunity threshold of 67% (R0 = 3) and an IFR of 0.6%, the absolute number of expected deaths across the globe would exceed 30 million people. Notably, this analysis assumes that IFRs do not vary across countries, and it does not consider factors that lead to heterogeneity in IFRs, including differences in access to healthcare resources and variation in the prevalence of comorbidities.

Epidemiological Considerations for SARS-CoV-2 Herd Immunity

Because SARS-CoV-2 is a novel pathogen, many features of its transmission and infection dynamics are not well characterized. Thus, our above analysis provides only a sense of the potential ramifications given a scenario in which we attain herd immunity via natural infection. We do not consider numerous complexities of viral spread and infectivity, including variation in R0 across time and populations, heterogeneity in the attack and contact rates across demographic groups, and inter-individual variation incommunicability and disease severity, although these aspects are essential to understand the full picture of SARS-CoV-2 community spread. While these epidemiological factors have important implications in the context of herd immunity, currently, they are difficult to estimate given the limited data available.

Differences in population density, cultural behaviors, population age structure, underlying comorbidity rates, and contact rates across groups influence transmission dynamics within communities, so the assumption of a uniform R0 across populations is not realistic. Further, variation in transmissibility between individuals may play a major role in SARS-CoV-2 spread. Super spreading events occur when circumstances favorable for high rates of transmission arise. These events involve a single index case infecting a large number of secondary contacts and are known to be important in driving outbreaks of infectious diseases, including SARS, Middle East respiratory syndrome (MERS), and measles [7].

Reports of SARS-CoV-2 super spreading events have been documented, suggesting that heterogeneity in infectivity may significantly impact the dynamics of its transmission [3]. Finally, the factors that influence inter-individual heterogeneity in COVID-19 susceptibility, clinical pathology, and disease outcome are not well understood. Reported differences in sex- and ethnicity-specific CFRs suggest that genetic, environmental, and social determinants likely underlie variation in susceptibility to COVID-19 and the severity of COVID-19 complications, although future studies are needed to explore this further [4].

Immunological Considerations for SARS-CoV-2 Herd Immunity

The ability to establish herd immunity against SARS-CoV-2 hinges on the assumption that infection with the virus generates sufficient, protective immunity. At present, the extent to which humans can generate sterilizing immunity to SARS-CoV-2 is unclear. A recent study assessing the possibility of SARS-CoV-2 reinfection in a small cohort of rhesus macaques found that reinfection was not able to occur 1 month after the first viral challenge, suggesting at least short-term sterilizing immunity in these animals [16]. In a cohort of 175 recovered COVID-19 patients, SARS-CoV-2-specific serum neutralizing antibodies (NAbs) were detected at considerable, albeit variable, titers in most (n = 165) individuals [13], indicating that the production of NAb against SARS-CoV-2 is relatively common.

Whereas these findings are promising, other important questions to consider are whether NAbtiters will

wane over time and how long acquired immunity will last. Previous studies in confirmed SARS patients have demonstrated that NAb responses against SARS-CoV persisted for several months to 2 years, although all individuals displayed low titers after about 15 months [11]. Further, elevated concentrations of specific antibodies to coronavirus 229E, one of the viruses responsible for the common cold, were found 1 year after infection, although these titers were not sufficient to prevent reinfection in all individuals [8].

Together, these studies suggest that protection against reinfection with coronavirus species tends to diminish given sufficient time, although longitudinal serological studies are needed to assess the duration of SARS-CoV-2 immunity. If this proves to also be true for SARS-CoV-2, persistent herd immunity may never be attained in the absence of recurrent vaccination. Indeed, modeling of the transmission dynamics of SARS-CoV-2 predicts that short-term immunity (~10 months) would give rise to annual outbreaks, while longer-term immunity (~2 years) would lead to biennial outbreaks [9]. Mass serological testing is now needed to determine how many individuals have been infected, how many individuals are immune, and how far we are from reaching the herd immunity threshold. That said, even if reinfection can occur after sterilizing immunity wanes, enduring memory cells of the adaptive immune system would likely facilitate immune control of the virus and limit disease pathology, which would hopefully decrease the clinical severity of subsequent infections.

References

1. Song Z, Xu Y, Bao L, Zhang L, Yu P, et al. (2019) From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 11: 59.https://doi.org/10.3390/v11010059

2. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967-1976.https://doi.org/10.1056/NEJMoa030747

3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367: 1814-1820.https://doi.org/10.1056/NEJMoa1211721

4. Wu F, Zhao S, Yu B, Chen YM, Wang W, et al. (2020) A new coronavirus associated with human respiratory disease in China. Nature 579: 265-269.https://dx.doi.org/10.1038/s41586-020-2008-3

5. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM (2020) COVID-19: Immunology and treatment options. Clin Immunol 215: 108448.https://doi.org/10.1016/j.clim.2020.108448

6. Anthony SJ, Johnson CK, Greig DJ, Kramer S, Che X, et al. (2020) Global patterns in coronavirus diversity. Virus Evol 3: vex012.https://doi.org/10.1093/ve/vex012

7. Tortorici MA, Veesler D (2019) Structural insights into coronavirus entry. Adv Virus Res 105: 93-116. https://doi.org/10.1016/bs.aivir.2019.08.002

8. Kleine-Weber H, Pohlmann S, Hoffmann M (2019) Spike proteins of novel MERS-coronavirus isolates from North- and West-African dromedary camels mediate robust viral entry into human target cells. Virology 535: 261-265.https://doi.org/10.1016/j.virol.2019.07.016

9. Hulswit RJ, de Haan CA, Bosch BJ (2016) Coronavirus spike protein and tropism changes. Adv Virus Res 96: 29-57.https://doi.org/10.1016/bs.aivir.2016.08.004

10. Ou X, Liu Y, Lei X, Li P, Mi D, et al. (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11: 1620.https://doi.org/10.1038/s41467-020-15562-9

11. Klausegger A, Strobl B, Regl G, Kaser A, Luytjes W, et al. (1999) Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus. J Virol 73: 3737-3743.https://doi.org/10.1128/JVI.73.5.3737-3743.1999

12. Chan JF, Yuan S, Kok KH, To KK, Chu H, et al. (2020) A familial cluster of pneumonia associated with

the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395: 514-523.https://doi.org/10.1016/S0140-6736(20)30154-9

13. Huang C, Wang Y, Li X, Ren L, Zhao J, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506.https://doi.org/10.1016/S0140-6736(20)30183-5

14. Lu R, Zhao X, Li J, Niu P, Yang B, et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395: 565-574.https://doi.org/10.1016/S0140-6736(20)30251-8

15. Prompetchara E, Ketloy C, Palaga T (2020) Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 38: 1-9.https://doi.org/10.12932/AP-200220-0772

16. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273.https://doi.org/10.1038/s41586-020-2012-7

17. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, et al. (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203: 631-637.https://doi.org/10.1002/path.1570

18. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, et al. (2005) Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol 79: 15511-15524.https://doi.org/10.1128/JVI.79.24.15511-15524.2005

19. Sungnak WH, Bécavin C, Berg M, Queen R, Litvinukova M, et al. (2020) HCA lung biological network. SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways. Nat Med 26: 681-687.https://doi.org/10.1038/s41591-020-0868-6

20. Xu H, Zhong L, Deng J, Peng J, Dan H, et al. (2020) High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 12: 8.https://doi.org/10.1038/s41368-020-0074-x

21. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, et al. (2020) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol 214: 108393.https://doi.org/10.1016/j.clim.2020.108393

22. Zhu N, Zhang D, Wang W, Li X, Yang B, et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382: 727-733.https://doi.org/10.1056/NEJMoa2001017

23. Perlman S, Dandekar AA (2005) Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol 5: 917-927.https://doi.org/10.1038/nri1732

24. Ben Addi A, Lefort A, Hua X, Libert F, Communi D, et al. (2008) Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol 38: 1610-1620.https://doi.org/10.1002/eji.200737781

25. Lazear HM, Schoggins JW, Diamond MS (2019) Shared and distinct functions of type I and type III interferons. Immunity 50: 907-923.https://doi.org/10.1016/j.immuni.2019.03.025

26. de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14: 523-534.https://doi.org/10.1038/nrmicro.2016.81

27. Alunno A, Padjen I, Fanouriakis A, Boumpas DT (2019) Pathogenic and therapeutic relevance of JAK/STAT signalling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells 8: 898.https://doi.org/10.3390/cells8080898

28. Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39: 529-539.https://doi.org/10.1007/s00281-017-0629-x

29. Kindler E, Thiel V, Weber F (2016) Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv Virus Res 96: 219-243.https://doi.org/10.1016/bs.aivir.2016.08.006

30. Lu X, Pan J, Tao J, Guo D (2011) SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes 42: 37-45.https://doi.org/10.1007/s11262-010-0544-x

31. Yi Y, Lagniton PNP, Ye S, Li E, Xu RH (2020) COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 16: 1753-1766.https://dx.doi.org/10.7150/ijbs.45134

32. Cron RQ, Chatham WW (2020) The rheumatologist's role in Covid-19. J Rheumatol 47: 639-642.https://doi.org/10.3899/jrheum.200334

33. Du Y, Tu L, Zhu P, Mu M, Wang R, et al. (2020) Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am. J Respir Crit Care Med 201: 1372-1379.https://doi.org/10.1164/rccm.202003-0543OC

34. Zumla A, Hui D, Perlman S (2015) Middle East respiratory syndrome. Lancet 386: 995-1007.https://doi.org/10.1016/S0140-6736(15)60454-8

35. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, et al. (2003) Lung pathology of fatal severe acute respiratory syndrome. Lancet 361: 1773-1778.https://doi.org/10.1016/S0140-6736(03)13413-7

36. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, et al. (2004) Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136: 95-103.https://doi.org/10.1111/j.1365-2249.2004.02415.x

37. Atkin-Smith GK, Duan M, Chen W, Poon IKH (2018) The induction and consequences of Influenza A virus-induced cell death. Cell Death Dis 9: 1002.https://doi.org/10.1038/s41419-018-1035-6

38. Fu Y, Cheng Y, Wu Y (2020) Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 35: 266-271.https://doi.org/10.1007/s12250-020-00207-4

39. Takada A, Kawaoka Y (2003) Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13: 387-398.https://doi.org/10.1002/rmv.405

40. Jin Y, Yang H, Ji W, Wu W, Chen S, et al. (2020) Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 12: 372.https://doi.org/10.3390/v12040372

41. Xu Z, Shi L, Wang Y, Zhang J, Huang L, et al. (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8: 420-422.https://doi.org/10.1016/S2213-2600(20)30076-X

42. Yao XH, Li TY, He ZC, Ping YF, Liu HW, et al. (2020) A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi 49: 411-417.https://doi.org/10.3760/cma.j.cn112151-20200312-00193

43. Schnabel A, Hedrich CM (2018) Childhood vasculitis. Front Pediatr 6: 421.https://doi.org/10.3389/fped.2018.00421

44. Guo XJ, Thomas PG (2017) New fronts emerge in the influenza cytokine storm. Semin Immunopathol 39: 541-550.https://doi.org/10.1007/s00281-017-0636-y

45. Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, et al. (2018) Cytokine release syndrome. J Immunother Cancer 6:56.https://doi.org/10.1186/s40425-018-0343-9

46. Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. Int Care Med 46: 846-848.https://doi.org/10.1007/s00134-020-05991-x

47. Qin C, Zhou L, Hu Z, Zhang S, Yang S, et al. (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan. China. Clin Infect Dis.

48. Chen G, Wu D, Guo W, Cao Y, Huang D, et al. (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest.https://doi.org/10.1172/JCI137244

49. Friedman MB, Schmid HA, Josef AS, Longton M (2015) Endotoxin/TLR3 signal transduction pathway: role in lung injury. Am J Biomed 3: 333-344.https://doi.org/10.18081/2333-5106/015-06/333-344

50. Yousif NG (2014) Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK–PI 3 K/A kt pathway. Cell Biol Int 38: 85-91.https://doi.org/10.1002/cbin.10184

51. Singer BS, Blinov SK (2014) The epidemiological characteristics ofEbola virus disease. Am J Biomed 2: 1095-1109.

Chapter -5

Diagnosis of COVID-19

Priorities for Testing Patients with Suspected Covid-19 Infection

COVID-19 Symptoms: Fever, Cough, and Shortness of Breath [1].

Priority 1

- Ensures optimal care options for all hospitalized patients, lessen the risk of healthcare-associated infections, and maintains the integrity of the healthcare system.
- Hospitalized patients.
- Healthcare facility workers with symptoms.

Priority 2

- Ensures those at the highest risk of complications of infection are rapidly identified and appropriately triaged.
- Patients in long-term care facilities with symptoms.
- Patients 65 years of age and older with symptoms.

Non-Priority: Individuals without symptoms.

Specimen Collections for COVID-19

Appropriate procedures for the various samples should be followed and collected before any sample is collected, which includes comprehensive staff training in collecting, packing, saving, and transporting appropriate samples. Specialists should also be aware of preventive measures and control guidelines for COVID-19, for this subject should follow WHO interim directives. The samples that have been taken are likely to be safe, so be careful when handling the samples. Clinical samples collected from suspected individuals should be diagnosed inappropriately equipped [2,3].

Biosafety Measures

Key points in biosafety in the diagnostic laboratory included [4]:

- All risk-based procedures must be conducted only by specialists, with strict adherence to any relevant protocols always.
- Samples must also be processed in a biosafety cabin (BSC) or primary containment device.
- Non-reproductive diagnostic laboratory work, for example, sequencing, and DNA amplification recognition [NAAT] must be performed in an annex using biosafety level 2 equivalent protocols (BSL-2).
- POC Chase can also work on the bench without using BSC when spot risks and appropriate precautions are assessed in place.
- When conducting such virus transplants or neutral analysis in a laboratory to contain the airflow in the direction of the internal direction (BSL-3).
- Appropriate sterile that has been proven to exist should be used against coated viruses such as hypochlorite [bleaching], ethanol.

Collection, Processing, and Laboratory Transfer of Samples

Samples are transported immediately after collection. During transport, the COVID-19 can be diagnosed after that sample transfer without delayshipped and sent through the maintenance of the cooling chain of 2-8℃. If in case the conveyor lot is used in case of delay. It can also be frozen to 20℃ or typically. In case of prolonged delay, put in -70℃ liquid hydrogen then transport, it is important to avoid frequent melting and freezing samples [5]. Transport within national borders must comply with existing and applicable rules systems. In the international transfer of samples, the United Nations model Regulations should be followed with other regulations according totransport and freight routes. As it is fashioned as follows, the sampling proceduresare shown as the following CDC 2020. After sample collection and packaging, the sample is well packed triangular the packaging is shipped as shown in Figure1 and sent to the nearest laboratory for receipt and testing, On the other hand, maintaining the suitable cooling chain [6].



Figure 1: Amplification plot.

For Initial Diagnostic Testing for COVID-19

CDC recommends collecting and testing an upper respiratory specimen. The nasopharyngeal specimen is the preferred choice for swab-based SARS-CoV-2 testing. When a collection of a nasopharyngeal swab is not possible, the following are acceptable alternatives [7]:

- Alternative specimens
- An oropharyngeal (OP) specimen
- A nasal mid-turbinate (NMT) swab collected
- An anterior naris (nasal swab; NS)

Specimen Types

Broncho alveolar lavage, tracheal aspirate: Collect 2-3 mL into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container.

Sputum: Have the patient rinse the mouth with water andthen expectorate deep cough sputum directly into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container.

Nasopharyngeal (NP) swab/oropharyngeal (OP) swab: Use only synthetic fiber swabs with plastic shafts. Do not use calcium alginate swabs or swabs with wooden shafts, as they may contain substances that inactivate some viruses and inhibit PCR testing.

Place swabs immediately into sterile tubes containing 2-3 mL of viral transport media(VTM)[8].

Nasopharyngeal swab: swab takes through the following steps

Insert

Nasopharyngeal swab: Insert a swab into the nostril parallel to the palate. The swab should reach depth equal to the distance from nostrils to the outer opening of the ear. Leave swab in place for several seconds to absorb secretions.

Remove

Gently remove swab while rotating it.

Oropharyngeal swab (e.g., throat swab): Swab the posterior pharynx, avoiding the tongue(Figure2).



Figure 2: Oropharyngeal swab.

Storage

Store specimens at 2-8°C for up to 72 hours after collection in VTM. If a delay in testing or shipping is expected, store specimens at -70°C or below. The larger of the two studies reported OP swabs detected the COVID-19 virus less frequently than NP swabs and should not be used in place of NP swabs. This difference was most notable at days 8+ after illness onset, with about a 20% point minimum difference in positive rates between OP and NP swabs. The difference was less at 0-7 days [9].

Patient Information on the Specimen Tube

- Patient name
- Patient date of birth
- Specimen collected date

- Specimen source (type)
- State of Illness

Laboratory Testing for COVID-19 Virus

Nucleic Acid Amplification Tests (NAAT): COVID-19 virus is based on the detection of unique sequences of virus RNA by real-time RT-PCR with confirmation by nucleic acid sequencing when necessary. The viral genes targeted so far include the N, E, S, and RdRP genes.

Why use real-time RT-PCR?

Because is extremely sensitive and specific and can deliver a reliable diagnosis as fast as three hours, is significantly faster and has a lower potential for contamination or errors as the entire process can be donewithin a closed tube. Detect past infections, which are important for understanding the development and spread of the virus, real-time RT-PCR cannot be used as viruses are only present in the body for a specific window of time (Figure 1). Other methods are necessary to detect, track, and study past infections, particularly those that may have developed and spread without symptoms [1,10].

Limitations of the Procedure

The procedures must be followed as described by the company. Any deviations may result in assay failure or cause erroneous results. Good laboratory practice is required to ensure the performance of the kit, with the care required to prevent contamination of the kit components. As with any molecular test, mutations within the target regions of the Primer Design Real-Time PCR assay could affect primer and/or probe binding failing to detect the presence of a virus [7].

False-negative results may be caused by:

- Unsuitable collection, handling, and/or storage of samples.
- Sample outside of the viremic phase.
- Use of unauthorized extraction kit or PCR platform.
- This test cannot rule out diseases caused by other pathogens.
- A negative result for any PCR test does not rule out the possibility of infection.

Serological testing: Serological surveys can aid investigation of an ongoing outbreak and retrospective assessment of the attack rate or extent of an outbreak. In cases where NAAT assays are negative and there is a strong epidemiological link to COVID-19 infection, paired serum samples (in the acute and convalescent-phase) could support the diagnosis. Cross reactivity to other coronaviruses can be challenging, some studies with COVID-19 serological data on clinical samples have been published [8,6].



Figure 3: COVID-19 IgM/IgG Rapid Test.

Viral sequencing: Useful to monitor for viral genome mutations that might affect the performance of medical countermeasures, including diagnostic tests. Virus whole-genome sequencing can also inform molecular epidemiology studies [3].

Viral culture: Virus isolation is not recommended as a routine diagnostic procedure. in vitro for SARS-CoV-2. However, the viral culture can be used for research related to studying the characteristics of the virus, such as isolating the virus, studying the characteristics of the virus and developing the vaccine, as the epithelial cell lines of the human airway were used for the initial isolation of the virus especially in a reference laboratory [7].

Warnings and Precautions

Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in areas where reagents and human specimens are handled.

Handle all specimens as if infectious using safe laboratory procedures. Perform all manipulations of potential live virus samples within a class II (or higher) biological safety cabinet.

Follow the necessary precautions when handling specimens. Use personal protective equipment (PPE) consistent with current guidelines for the handling of potentially infectious samples [6,11].

References

1. US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) information, and a list of all current EUAs. United States.
2. World Health Organization (2020) Coronavirus disease (COVID-19) technical guidance: surveillance and case definitions. Switzerland.
3. World Health Organization (2004) Laboratory biosafety manual: third edition. Switzerland.
4. Centers for Disease Control and Prevention (2020) CDC 2019-Novel Coronavirus (2019-nCoV) Realtime RT-PCR Diagnostic Panel. United States.
5. Liang G, Lazenby D, Groden JD, Liu X, Pretlow SN, et al. (2014) Aryl hydrocarbon receptor protects against viridans streptococci infection by activation of immune system through IL-17RA signaling. AmJ BioMed2:527-554.
6. Center for Disease Control and Prevention (2020) Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings. United States.
7. Center for Disease Control and Prevention (2020) Interim Laboratory Biosafety Guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19). United States.
8. Center for Disease Control and Prevention (2020) Interim Guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19). United States.
9. Hopman J, Allegranzi B, Mehtar S (2020) Managing COVID-19 in low- and middle-income countries. JAMA 323: 1549-1550.https://doi.org/10.1001/jama.2020.4169
10. World Health Organization (2020) Naming the coronavirus disease (COVID-19) and the virus that causes it. Switzerland.
11. World Health Organization(2020) Novel coronavirus (2019-nCoV) situation reports. Switzerland.

Chapter -6

Treatment and Prevention

Chapter Overview

Despite worldwide efforts since the initial identification of Coronavirus disease 2019 (Covid-19) at the end of 2019 [1]. To the date of writing the chapter of this book, there is no effective cure to this malady which had changed dramatically the way we live. This pandemic had stimulated the researchers from every part of the world to investigate hundreds of drugs or treatment intervention. The Ministry of Health, Labor and Welfare will confirm on May 12 that COVID-19 has been confirmed to have a certain level of efficacy and safety as a result of public research projects for drugs, medical devices, in-vitro diagnostic drugs, regenerative medicine products, etc. Has issued a notice that it is possible to apply for approval without waiting for clinical trial results. It is stated that "medicals for new-type coronavirus infectious diseases will be examined with the highest priority", and we plan to put therapeutic drugs into practical use as soon as possible.

In the other hand, the Japan Medical Association's "COVID-19 Conference of Experts" said on May 17th, "Understanding the special administrative procedures for speeding up approval," he said, "Even though it is an emergency, the scientific basis is insufficient. It is clear that no candidate drug should be approved as a therapeutic drug". Randomized controlled trials with appropriate control groups are essential for the development of the COVID-19 therapeutics, and should be approved based on sufficient scientific evidence from clinical trials, he said.

In this chapter, we will try to cover the remedies that had been used to fight this illness and had shown some benefit by initial studies or had gain public attention but later proofed useless and even harmful like hydroxychloroquine.Covid-19 is an emerging, rapidly evolving situation. At the time of writing this chapter, many clinical trials are ongoing to rule in or rule out drug or therapeutic intervention so many facts mentioned now may be false tomorrow.

Treatments categories:

1. Infection Control
2. Supportive Care
    - Nutritional support
    - Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    - Hemodynamic Support
    - Ventilatory Support
3. Antiviral Drugs
    - Protease inhibitors (PIs).
    - RNA polymerase inhibitors.
    - Endosomal acidification inhibitors (Antimalaria drugs).
    - Membrane fusion inhibitors and inhibitors of ACE2 receptor connection
    - Other drugs with antiviral activity.
4. Immunomodulatory and anti-inflammatory drugs:

- Monoclonal antibodies
- Anti-rheumatic drugs
- Macrolide antibiotics
- Corticosteroid
- Interferons
- The anti-fibrotic agent

5. Passive immunization
    - Convalescent plasma
    - Immunoglobulins
6. Anti-thrombotic Agents
7. Cell therapies
8. Investigational Devices

Infection Control: Before discussion of treatment we should prevent further spread of the disease the NIH guidelines recommend: "For health care workers who are performing aerosol-generating procedures on patients with COVID-19, the COVID-19 Treatment Guidelines Panel (the Panel) recommends using fit-tested respirators (N95 respirators) or powered air-purifying respirators, rather than surgical masks, in addition to other personal protective equipment (i.e., gloves, gown, and eye protection such as a face shield or safety goggles) (AIII) [2].

Supportive Care

Nutritional support: Nutrition is of paramount importance to good health [3]. In 2014-2016, the Ebola virus outbreak immediate nutritional support demonstrated to significantly reduce the case fatality rate. This may also apply to the Covid-19 pandemic [4].

1. **Vitamin C:**Vitamin C is well-known for its antioxidant characteristic, acts as free radical scavenger enables the body to get rid of reactive oxygen species. Also, it supports the health of the immune system and during infection, its levels can become depleted. The requirement for vitamin C increases in parallel with the severity of the infection [5]. A clinical trial is ongoing currently to test high-dose of I.V vitamin C (24 g/day for 7 days) in patients with COVID-19.
2. In this trial, we have placebo control and both group assessed for the need for vasopressor drugs and mechanical ventilation, ICU length of stay, organ failure scores and 28-day mortality [6].
3. **Vitamin D:** J. M. Rhodes and associate studied the effect of vitamin D on Covid-19 pandemic and concluded:
    - Vitamin D deficiency as a possible factor determining the COVID-19 severity.
    - Lower population mortality in countries south of 28 degrees N latitude where there will have been sufficient sunlight to maintain vitamin D levels during the past months.
    - Vitamin D deficiency correlates with hypertension, diabetes, obesity, ethnicity and institutionalization all of which are features associated with increased risk of severe COVID-19.
    - Vitamin D moderates inflammatory cytokine response by macrophages and respiratory epithelial cells to pathogens including respiratory viruses.
    - Vitamin D's effect on cytokines and reduced risk for experimental lung injury is likely

mediated by its increase in ACE2: ACE ratio and consequential reduction of angiotensin II – highly relevant to COVID-19 since ACE2 is the SARS-CoV-2 receptor.

- Vitamin D deficiency and vitamin D receptor polymorphisms are associated with an increased risk of severe viral bronchiolitis in infants.
- Vitamin D deficiency is easily prevented by supplementation which is very safe [7].



Figure 1: Postulated mechanisms of zinc action in Covid-19 (8).

Zinc

Regardless of all the above theories on the beneficial effect of zinc supplement in covid-19, there is no clinical evidence to prove that yet. A retrospective study concluded a lack of a causal association between zinc and survival in a patient hospitalized for COVID-19 [9].

- **Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):** The WHO did a rapid systematic review on 20 March 2020 on NSAIDs and viral respiratory infections and concluded: "At present, there is no evidence of severe adverse events, acute health care utilization, long-term survival, or quality of life in patients with COVID-19, as a result of the use of NSAIDs." [10].
- **Hemodynamic Support:** The vasopressor of choice in critical cases with hemodynamic collapse is norepinephrine. And in refractory shock low dose corticosteroid can be used [2].
- **Ventilatory Support:** In a patient with acute hypoxemic respiratory failure despite conventional oxygen therapy high-flow nasal cannula (HFNC) (Figure 2) oxygen is recommended.When high flow nasal cannula is not available noninvasive positive pressure ventilation (NIPPV) (Figure 3) with close monitoring can be used in the absence of an indication for intubation. Endotracheal intubation should be done by an experienced person when needed [2].

The awake prone position is optional and recommended by experts in patients who don't needintubation but no well-designed studies prove its benefit. It should be avoided in patients who need intubation and mechanical ventilation.

Low tidal volume (VT) ventilation (VT 4-8 mL/kg of predicted body weight) is recommended during mechanical ventilation.12 to 16 hours/day prone ventilation is advised in refractory hypoxemia [2].

(ECMO) extracorporeal membrane oxygenation: insufficient data are currently available to recommend either for or against the routine use of it in patients with COVID-19 and refractory hypoxemia [2].



Figure 2: High flow nasal cannula (11).



Figure 3: Noninvasive Positive Pressure Ventilation (Nippv) (12).



Figure 4: Sites of action of different drugs and therapeutic intervention used to treat Covid-19 (13).

Antiviral Drugs

Protease inhibitors (PIs):

- **Lopinavir:** one of the drugs used to treat human immunodeficiency virus 1 (HIV-1) infection. Protease inhibitors act by inhibiting the viral enzyme that is responsible for cleavage of the large nonfunctional polyprotein precursor into smaller functional viral protein (see video https://youtu.be/MK2r8J7SCSg).
- 3C-like proteinase is the main coronavirus proteinase and it is the site of action of protease inhibitor [14]. Protease inhibitor were used previously in the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) and were shown to be effective [15,16].
- **Ritonavir** is a cytochrome P450-3A4 inhibitor used to boost lopinavir by increasing its half-life [17].
- **+Lopinavir/ritonavir** combination with or without other drugs has been used successfully to reduce adverse outcomes [18]. Other PIs are: ritonavir boosted ASC09 (a novel PI), cobicistat boosted darunavir and the NS3/4A protease inhibitor danoprevir combined with ritonavir.
- The **NIH** (Nasional institute of health) Panel for COVID-19 Treatment Guidelines advised against lopinavir/ritonavir use or other HIV protease inhibitors [19]. The Infectious Diseases Society of America (IDSA) guidelines recommend lopinavir/ritonavir use in the context of a randomized clinical trial only [20]. Therecovery trial On June 29, 2020, concluded that there is no benefit of lopinavir/ritonavir compared with those who received standard care in hospitalized patients with COVID-19 [21].

RNA polymerase inhibitors: They are nucleotide analogs and compete with the natural nucleotides for the active site of the RNA-dependent RNA polymerase thus inhibiting viral replication (see video https://youtu.be/GZucJzAmYhM). **Sofosbuvir, Ribavirin**, and**Remdesivir** are already used previously for other viruses with known safety profiles[22]. The adenosine analog Remdesivir (GS-5734™) is a broad spectrum antivirus and can overcome the proof reading of exonuclease and genetic resistance[23].

On the 1st of May 2020, FDA stated "the U.S. Food and Drug Administration issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the hospital with COVID-19, the investigational drug was shown in a clinical trial to shorten the time to recovery in some patients" [24]. Remdesevir had shown to decrease mortality at day 14 when compared to standard care in severe cases of Covid-19 [25].

Favipiravir is another nucleoside analog used previously for the influenza virus also is a wide spectrum

antivirus. In vitro had shown to be effective against Covid-19 and currently is under investigation in clinical trials [26].

Other RNA polymerase inhibitors that are under investigation: **MK-4482** and **AT-527**

A guanosine analog **Ribavirin** inhibits synthesis of guanosine triphosphate by acting on the enzyme inosine monophosphate dehydrogenase causing lethal mutation in the RNA genome. Ribavirin was used previously in the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV) and is investigated now for Covid-19 [27].

Other nucleoside analogs that inhibit viral reverse transcriptase which on the investigation are;**Azvudine**(azido cytidine analogue), **emtricitabine**, **tenofovir** and **alafenamide**.

Endosomal acidification inhibitors (Antimalaria drugs):

Chloroquine and hydroxychloroquine are malaria drugs and used in autoimmune diseases [28]. They had antiviral activity in vitro but never confirmed in vivo [29]. They act a weak base and concentrate in the acidic intracellular organelles thus increase the PH inside it leading to impairment of viral cell fusion, uncoating and viral replication which are all PH dependent steps [30].

Chloroquine and hydroxychloroquine are accumulated in lymphocytes and macrophages, and decrease the secretion of pro-inflammatory cytokines, in particular tumor necrosis factor-alpha (TNF-α) [31].

On June 15, 2020, the FDA stated "the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible. The agency determined that the legal criteria for issuing a EUA are no longer met. Based on its ongoing analysis of the EUA and emerging scientific data, the FDA determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. Additionally, in light of ongoing serious cardiac adverse events and other potentially serious side effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorized use" [31].

A double-blind randomized trial done in the University of Minnesota concluded no benefit of hydroxychloroquine in preventing illness due to COVID-19 when compared to placebo in post exposure prophylaxis in asymptomatic people when taken within 4 days after high-risk or moderate-risk exposure [32].

Solidarity is global a trial organized by the WHO in which confirmed cases of COVD-19 are randomized to standard care or one of four treatment arms (chloroquine or hydroxychloroquine, remdesivir, lopinavir/ritonavir, or lopinavir/ritonavir plus interferon beta-1a). On July 4, 2020, the treatment arms of hydroxychloroquine, chloroquine and lopinavir/ritonavir have been stopped due to the unproven benefit of the drugs in a reduction in mortality when compared to the standard care [33].

Membrane Fusion Inhibitors and Inhibitors of ACE2 Receptor Connection

The novel Covid-19 virus spike protein (S-protein) binds host epithelial cells membrane through the ACE2 receptor and anther host cell membrane protein called type II transmembrane serine protease (TMPRSS2) facilitates membrane fusion and enhance viral internalization by S-protein activating. These membrane proteins, are an integral part of the Covid-19 life cycle and are possible therapeutic targets [34,35].

ACEIs and ARBs may have a detrimental effect through increase expression of ACE2 receptors potentially increase susceptibility to severe COVID-19 by enhancing viral cellular entry [36].

Vaduganathan M, etal. (2020)[34] studied the Renin-Angiotensin-Aldosterone system inhibitors in patients with Covid-19 and concluded:

"ACE2, an enzyme that physiologically counters RAAS activation, is the functional receptor to SARS-CoV-2, the virus responsible for the Covid-19 pandemic. Preclinical studies have suggested that RAAS

inhibitors may increase ACE2 expression, raising concerns regarding their safety in patients with Covid-19. Insufficient data are available to determine whether these observations readily translate to humans, and no studies have evaluated the effects of RAAS inhibitors in Covid-19. Clinical trials are underway to test the safety and efficacy of RAAS modulators, including recombinant human ACE2 and the ARB losartan in Covid-19. Abrupt withdrawal of RAAS inhibitors in high-risk patients, including those who have heart failure or have had a myocardial infarction, may result in clinical instability and adverse health outcomes. Until further data are available, we think that RAAS inhibitors should be continued in patients in otherwise stable conditions who are at risk for, being evaluated for, or with Covid-19" [37].



Figure 2: Interaction between Sars-Cov-2 and the renin–angiotensin–aldosterone system (37).

Umifenovir (Arbidol) Antiviral drug used in China and Russia for influenza treatment. In binds to hemagglutinin protein. It also targets the spike glycoproteins of SARS-CoV-2 (similar to that of H3N2) as speculated in structural and molecular dynamics study [34]. In China, a retrospective study of non-ICU hospitalized patients with COVID-19 did not show an improved outcome [38]. An exploratory randomized controlled trial study that compared lopinavir/ritonavir or umifenovir monotherapy with standard care in patients with mild-to-moderate COVID-19 concluded no statistical difference between each treatment group [39].

Other drugs with antiviral activity

- **Nitazoxanide** (NT-300; Romark Laboratories): inhibit viral replication in cell culture of many respiratory viruses including SARS-CoV-2. A multicenter, randomized, double-blind clinical trial was recently initiated [40].
- **Ivermectin** an ant parasitic drug has antiviral activity against SARS-CoV-2 but the concentration needed to be effective in vivo may be very high and concern about Efficacy, neurotoxicity, drug interactions [41]. A retrospective cohort study was done at four Florida hospitals on patients with confirmed Covid-19 infection concluded that Ivermectin lower mortality in the treatment of COVID-19, particularly in patients on higher oxygen concentration orventilatory support [42].
- **Merimepodib**the mechanism of is inhibition of inosine-5'-monophosphate dehydrogenase (IMPDH), leads to a depletion of guanosine for use by the viral polymerase during replication [43].

- **Niclosamide** Anthelmintic agent that has potential use as an antiviral agent.

Others: all are currently being investigated

- **Rintatolimod** (Toll-like receptor 3 (TLR-3) agonist)
- **Beta-D-N4-hydroxycytidine** orally bioavailable broad-spectrum antiviral.
- **Bemcentinib**Selective oral AXL kinase inhibitor.
- **VIR-2703** targets small interfering RNA
- **Trabedersen** inhibits transforming growth factor (TGF)-beta2 expression.
- **Antroquinonol** Antiviral/anti-inflammatory agent.
- **Apilimoddimesylate** Inhibits the lipid kinase enzyme.

Immunomodulators and anti-inflammatory drugs: Cytokine storm syndrome (CSS) and hemophagocytic lymphohistiocytosis (HLH) resulted from an immune response against the virus are the usual cause of acute respiratory distress syndrome (ARDS) and multi-organ failure in the severe Covid-19 infection that leads to death. This the rationale beyond immunosuppressive use [44].

Monoclonal Antibodies

In critically ill patients with Covid-19, there had been observed a significantly higher level of interleukin-6 (IL-6).**Tocilizumab** and **sarilumab** are monoclonal antibodies against the interleukin-6 receptor. In a study done in China, there is improved symptom and laboratory parameter with the use of Tocilizumab [45].

On June 11, 2020, the NIH announced "There are insufficient data to recommend either for or against the use of interleukin-6 (IL-6) inhibitors (e.g., sarilumab, **siltuximab,** and tocilizumab) for the treatment of COVID-19" [46].

July 2020 results from the **COVACTA** trial show only a decrease in hospitalization time among patients in the tocilizumab arm [47].

Other monoclonal antibodies being tested now in the treatment of Covid-19:

1. **Anakinra**: IL-1 receptor antagonist
2. **Adalimumab**: tumor necrosis alfa antagonist
3. **Ixekizumab**: IL-17a receptor antagonist
4. **Neubevacizumab**: Vascular endothelial growth factor-A antagonist
5. **Baricitinib**: Janus kinase inhibitors
6. **Ifenprodil**: N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist
7. **Eculizumab**: Modulates the activity of terminal complement to prevent the formation of the membrane attack complex
8. **Aviptadil**: Synthetic vasoactive intestinal peptide
9. **Tradipitant**: Neurokinin-1 (NK-1) receptor antagonist.
10. **Gimsilumab**: A monoclonal antibody that targets granulocyte macrophage-colony stimulating factor

11. **Acalabrutinib**: tyrosine kinase inhibitor
12. **Osmapimod**: Selective inhibitor of p38alpha/beta mitogen activated protein kinase (MAPK)
13. **Leronlimab**: CCR5 antagonist.
14. **Abivertinib** Tyrosine kinase inhibitor
15. **Aprepitant**Substance P/neurokinin-1
16. **Lenzilumab**Monoclonal antibody directed against GM-CSF.
17. **LY3127804** Selective monoclonal antibody against angiopoietin 2

Anti-rheumatic drugs

Leflunomide, thalidomide and colchicine are immunomodulators licensed for hematological and rheumatological disease (act by inhibiting the assembly of the NLRP3 inflammasome) [48]. They are also being investigated in the treatment of Covid-19.

Macrolide antibiotics

Macrolide antibiotics have immunomodulatory effects and pharmacodynamic properties to achieve a higher concentration in the pulmonary epithelial fluid than in serum, have tempted investigators to repurpose them against Covid-19 [49].

Chloroquine, hydroxychloroquine, and azithromycin combination is associated with significant QT prolongation and may lead to an increased risk of cardiac death. Because of that, the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society all warned against this combination [50].

Corticosteroid

The European Society of Intensive Care Medicine recommends the use of corticosteroid in a critically ill patient with Cocid-19 when there is shock, evidence of Cytokine storm syndrome, hemophagocytic lymphohistiocytosis and/or mechanically ventilated patients with ARDS [51].

Earlier in February 2020, a study stated against the use of corticosteroid "No clinical data exist to indicate that net benefit is derived from corticosteroids in the treatment of respiratory infection due to RSV, influenza, SARS-CoV, or MERS-CoV. The available observational data suggest increased mortality and secondary infection rates in influenza, impaired clearance of SARS-CoV and MERS-CoV, and complications of corticosteroid therapy in survivors. If it is present, the effect of steroids on mortality in those with septic shock is small and is unlikely to be generalizable to shock in the context of severe respiratory failure due to 2019-nCoV.Overall, no unique reason exists to expect that patients with the 2019-nCoV infection will benefit from corticosteroids, and they might be more likely to be harmed with such treatment. We conclude that corticosteroid treatment should not be used for the treatment of 2019-nCoV-induced lung injury or shock outside of a clinical trial" [52].

Later on, The UK RECOVERY trial concluded that "In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support" [53].

A 5-day course of high-dose corticosteroids is shown to be associated with lowered hospital mortality rates, accelerated respiratory recovery, and decrease the likelihood of the need of mechanical ventilation in patients with severe COVID-19 pneumonia when compared to historical controls [54].Early glucocorticoid treatment (i.e., within 48 hours of admission) reduced mortality rates or mechanical ventilation need in patients with initial C-reactive protein (CRP) levels of 20 mg/dL or greater [55].

Interferons

Normal interferon response is suppressed in some people with Covid-19. In the laboratory, type 1 interferon can inhibit SARS-CoV-2, SARS-CoV and MERS-CoV. A randomized, controlled clinical trial involving antiviral remdesivir plus the immunomodulatory interferon beta-1a in patients with Covid-19. The study is called the ACTT 3 planned to enroll more than 1,000 hospitalized patients with Covid-19 [56].

The anti-fibrotic Agent

Pulmonary fibrosis has been observed in survivors of severe COVID-19 disease but the mechanism is not fully elucidated [57]. The pro-inflammatory cytokines (interleukin-1 interleukin-6 and other) mediate the abnormal immune response causing a persistent lung injury and fibrosis [58,59]. The anti-fibrotic agent pirfenidone is being evaluated in the prevention of post-COVID-19 pneumonia pulmonary fibrosis in at least three randomized clinical trials. In vitro, pirfenidone inhibits collagen synthesis by inhibiting transforming growth factor beta resulting in decrease extracellular matrix deposition and ameliorating lung fibroblasts [50].

IV. Passive immunization

1- Convalescent plasma



Figure (3): Convalescent plasma contains the neutralizing antibodies for the virus (51).

Convalescent plasma (CP) previously used to in treatment of Ebola virus when no other treatment was available (52). In SARS epidemic; retrospective studies showed that Convalescent plasma decrease hospitalization and mortality when ribavirin and corticosteroids treatment failed (53).

In SARS-CoV and influenza-A 2009 pandemic strain (H1N1pdm09) Convalescent plasma when given early in the course of the disease had shown to decrease mortality by 75% with no serious adverse effects (54).

A case series of 10 patients with Covid-19 reported from china on April 2020 stated: "This study showed

CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials." (55).

A multicenter study conducted by the Mayo Clinic concluded the following: "In summary, the experience of the first 5000 patients with COVID-19 transfused with convalescent plasma provides no signal of toxicity beyond what is expected from plasma use in severely ill patients. Additionally, given the deadly nature of COVID-19 and the large population of critically ill patients with multiple comorbidities included in these analyses, the mortality rate does not appear excessive. We also note that the data were reviewed by an independent Data and Safety Monitoring Board and have been deposited with the FDA and at no time was there consideration of stopping this therapy. Given the accelerating deployment of this therapy, these emerging data provide early safety indicators of convalescent plasma for COVID-19 treatment and suggest that research should shift focus toward determining the efficacy of convalescent plasma" (56).

Immunoglobulins

Immune globulin IV (Octagam 10%; Octapharma)

The FDA accepted phase 3 randomized trial to assess efficacy and safety the IV immunoglobulin in patients with severe COVID-19 disease (57).

Other immunoglobulin under investigation are:

Anti-SARS-CoV-2 polyclonal hyper immune globulin (Takeda)

REGN-COV2 Anti-Viral Antibody Cocktail

Polyclonal hyper immune immunoglobulin (TAK-888; Takeda) virus-specific antibodies concentrate extracted from plasma of recovered patients.

Anti-thrombotic Agents: On 12 may 2020 the NIH recommended:

"For non-hospitalized patients with Covid-19, anticoagulants and antiplatelet therapy should not be initiated for the prevention of venous thromboembolism (VTE) or arterial thrombosis unless there are other indications.

Hospitalized adults with Covid-19 should receive VTE prophylaxis per the standard of care for other hospitalized adults. Anticoagulant or antiplatelet therapy should not be used to prevent arterial thrombosis outside of the usual standard of care for patients without Covid-19.The reported incidence of VTE in hospitalized patients with Covid-19 varies. There are currently insufficient data to recommend for or against the use of thrombolytic or increasing anticoagulant doses for VTE prophylaxis in hospitalized Covid-19 patients outside the setting of a clinical trial.

There are currently insufficient data to recommend for or against routine deep vein thrombosis screening in Covid-19 patients without signs or symptoms of VTE, regardless of the status of their coagulation markers.

For hospitalized Covid-19 patients, the possibility of thromboembolic disease should be evaluated in the event of the rapid deterioration of pulmonary, cardiac, or neurological function, or of sudden, localized loss of peripheral perfusion" [58].



Figure 4: After the intravenous transplantation of mscs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction(58).

Mesenchymal stromal cells (MSCs) have immunomodulating properties, already used and have shown promise in the H5N1 influenza virus associated with acute lung injury in preclinical models [59]. In Beijing YouAn Hospital (affiliated with Capital Medical University, China) seven patients with COVID-19 pneumonia had intravenous MSC transplantation and resulted in significant improvement or cure of respiratory function and symptoms with no adverse effects. MSCs act by improving the lung microenvironment and significantly induce regulatory dendritic cells with a shift from Th1 to Th2 immune responses [60]. A clinical trial to use cell therapy like (allogeneic natural killer (NK) cells, autologous adipose-derived mesenchymal stem cells and bone marrow-derived allogeneic mesenchymal stem cell) for treatment of Covid-19 are ongoing.

Investigational Devices

Blood purification devices

CytoSorb, oXiris, Seraph 100 Microbind, Spectra Optia Apheresis all are extracorporeal blood purification filters used in continuous renal replacement therapy or the reduction of proinflammatory cytokines levels and have received emergency use authorization from the FDA for the treatment of COVID-19 with respiratory failure [59].

Nanosponges

Plasma membranes are derived from type II pneumocytes or human macrophages. They have the same protein receptors required by the Covid-19 virus for cellular entry and can deceive the virus [61].

Prevention

Diseases caused by the virus can range from mild infections to catastrophes that may affect the world. Because of the great variations in viruses and its strains and their epidemiology and pathogenesis, there is

no single approach to control the infections. This chapter tries to cover methods useful to various degrees in controlling covid-19.

An important principle that may affect the control of viral diseases include:

- Viral infections may be subclinical.
- Variety of viruses may have the same presentations.
- The virus itself may cause various diseases.
- Environmental and genetic factors for both the host and the virus.

The method of control of viral diseases include:

1. Vector control and improve sanitation: this can be achieved by reducing exposure of the host to the virus by revoking the vectors and animal reservoirs while improving sanitation applied to those viruses that are transmitted through the fecal oral route.

2. Immunoprophylaxis: including the use of a vaccine (active prophylaxis) or the use of antibody containing formula (passive prophylaxis).

3. Antiviral chemotherapy: these drugs may act either by inactivate the virus or inhibit the replication of the virus or immunomodulation that may augment the immune response of the host.

4. The use of interferons and cytokines: Interferon alpha is used successfully for many viral diseases in humans and the cytokines may change the biological response.

5. Infection control and prevention during a pandemic:Scientists are still learning about the pathogenesis of the disease, and think that the virus began in animals. At some time, one or more humans acquired infection from an animal, and those infected humans start transmitting the infection to other humans.

Measures to prevent transmission in people are an important priorityto:

- slow the demand for specialized wards, such as intensive care unit (ICU);
- protect the highest risk groups;
- protect healthcare workers
- reduce the transmission of cases to other healthcare facilities.

Coronaviruses are widely believed to be transmitted from person to person via large respiratory droplets (inhaled or deposited on different mucosal surfaces). Other routes that may play a role in the transmission of coronaviruses include contact with contaminated tools and possible inhalation of aerosols produced by aerosol generating procedures (AGPs). Also,the SARS-CoV-2 virus has been detected in respiratory and fecal specimens. On rare occasions, Viral RNA has also been detected in blood specimens but till now there is no evidence of transmission through contact with blood or blood products. The relative role and importance of droplet, tools and aerosol transmission for SARS-CoV-2, the protection provided by the different components of personal protective equipment (PPE) and the transmission of the virus at different stages of the disease remain still unclear.

General measures for control and prevention

Due to the possible transmission of the virus by persons with few symptoms or asymptomatic, so physical distancing measures are implemented by the staff, visitors and patients, particularly in communities withthe widespread transmission. The use of surgical masks by medical staff for personal protection and source control can be considered as one measure for reducing transmission within healthcare settings.

Optimal methods for protection have not been defined but any strategy needs to take into consideration the availability of surgical masks, the extent of community transmission and other available measures in the country. Some healthcare facilities clamped that all healthcare providers wear a surgical mask while at work. In countries with high community transmission, wearingsurgical masks or FFP2 respirators, if available, should be considered - in addition to standard precautions, such as the regular practice of meticulous hand hygiene by all healthcare staff providing care to patients.

Best Health Practices

There is currently no vaccine or treatment for COVID-19 Infection can be prevented by observing personal hygiene practices:

- Hand Washing

Wash your hands regularly with soap and water or alcohol-based hand rub.

- Vaccines

Make sure you have received all the recommended vaccines. Influenza Vaccine, if the influenza vaccine is available in your community, you should try to obtain it. The influenza virus causes symptoms similar to 2019-nCoV.

- you can reduce the likelihood of needing to visit a health care facility for evaluation of respiratory infection. If you develop fever, cough, and/or difficulty in breathing:

- Cover your coughor sneeze in your inner flexed arm/elbow or on a tissue paper.

- Stay at home, if you have mild symptoms. Do not go to school, to work, or to other public places until you are completely free of all symptoms.

- Health Facility, if you have more severe symptoms go to a medical facility and immediately notify the first person you encounter that you are worried that you have a respiratory infection.

References

1. Centers for Disease Control and Prevention (2020)How COVID-19 spreads.United States.
2. Murthy S, Gomersall CD, Fowler RA (2020) Care of critically ill patients with COVID-19. JAMA 323: 1499-500.https://doi.org/10.1001/jama.2020.3633
3. Covinsky K, Katz M (2020) Supplemental nutrition assistance program - Do not take the food out of patients' mouth. JAMA Intern Med 180: 605-606.https://doi.org/10.1001/jamainternmed.2019.7151
4. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, et al. (2015) Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med372:40-47.https://doi.org/10.1056/NEJMoa1411249
5. Carr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, et al. (2017) Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Crit Care 21:300.https://doi.org/10.1186/s13054-017-1891-y
6. Carr AC (2020) A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care 24:1-2.https://doi.org/10.1186/s13054-020-02851-4
7. Rhodes JM, Subramanian S, Laird E, Griffin G, Kenny RA () Perspective: Vitamin D deficiency and COVID-19 severity- plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis. J Intern Med.https://doi.org/10.1111/joim.13149
8. Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, et al. (2020) Zinc and respiratory tract infections: Perspectives for COVID-19. Int J Mol Med46: 17-26.https://doi.org/10.3892/ijmm.2020.4575

9. Yao JS, Paguio JA, Dee EC, Tan HC, Moulick A, et al. (2020) The minimal effect of zinc on the survival of hospitalized patients with COVID-19. An observational study. Chest.https://dx.doi.org/10.1016/j.chest.2020.06.082

10. World Health Organization (2020) The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19: scientific brief.Switzerland.

11. https://en.wikipedia.org/wiki/Non-invasive_ventilation#/media/File:BIPAP.JPG

12. Fragkou PC, Belhadi D, Peiffer-Smadja N, Moschopoulos CD, Lescure FX, et al. (2020) Review of trials currently testing treatment and prevention of COVID-19. Clin MicrobiolInfect26: 988-998.https://doi.org/10.1016/j.cmi.2020.05.019

13. Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, et al.(2020) α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J Med Chem63:4562-4578.https://doi.org/10.1021/acs.jmedchem.9b01828

14. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, et al. (2004) In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol31:69-75.https://doi.org/10.1016/j.jcv.2004.03.003

15. De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, Van Nieuwkoop S, et al.(2014) Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother58:4875-4884. https://doi.org/10.1128/AAC.03011-14

16. Kaletra Prescribing Information (2020).

17. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, et al. (2020) Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci35:e79.https://dx.doi.org/10.3346/jkms.2020.35.e79

18. National Institute of Health (2020) Potential antiviral drugs under evaluation for the treatment of COVID-19 Treatment guideline.United States.

19. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, et al. (2020) Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19.Clin Infect Dis. https://doi.org/10.1093/cid/ciaa478

20. Horby P, LandrayM (2020) No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY. Recovery Trial Net.

21. Elfiky AA (2020) Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci248:117477. https://doi.org/10.1016/j.lfs.2020.117477

22. Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, et al. (2020) Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Clin Infect Dis ciaa1041.https://doi.org/10.1093/cid/ciaa1041

23. Delang L, Abdelnabi R, Neyts J (2018) Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir Res153:85-94.https://doi.org/10.1016/j.antiviral.2018.03.003

24. Koren G, King S, Knowles S, Phillips E (2003) Ribavirin in the treatment of SARS: a new trick for an old drug? CMAJ168:1289-1292.

25. Rolain JM, Colson P, Raoult D (2008) Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents30:297-308.https://doi.org/10.1016/j.ijantimicag.2007.05.015

26. Touret F, de Lamballerie X (2020)Chloroquine and COVID-19. Antivir Res177: 104762.https://doi.org/10.1016/j.antiviral.2020.104762

27. Colson P, Rolain JM, Raoult D (2020) Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents55:105923.https://dx.doi.org/10.1016/j.ijantimicag.2020.105923

28. US Food and Drug Administration (2020) Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. United States.

29. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, et al. (2020) A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 383: 517-525.https://doi.org/10.1056/NEJMoa2016638

30. World Health Organization (2020) "Solidarity" clinical trial for COVID-19 treatments.Switzerland.

31. Chen Y, Guo Y, Pan Y, Zhao ZJ (2020) Structure analysis of the receptor binding of 2019-nCoV. BiochemBiophys Res Commun525:135-140.https://doi.org/10.1016/j.bbrc.2020.02.071

32. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O,et al. (2014) TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol88:293-1307.https://doi.org/10.1128/JVI.02202-13

33. Fang L, Karakuilakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med 8: e21.https://dx.doi.org/10.1016/S2213-2600(20)30116-8

34. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, et al.(2020) Renin–Angiotensin–Aldosterone system inhibitors in patients with Covid-19. N Engl J Med 382:1653-1659.https://doi.org/10.1056/NEJMsr2005760

35. Lian N, Xie H, Lin S, Huang J, Zhao J, et al. (2020) Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect26: 917-921.https://doi.org/10.1016/j.cmi.2020.04.026

36. Li Y, Xie Z, Lin W, Cai W, Wen C, et al. (2020) Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med.https://doi.org/10.1016/j.medj.2020.04.001

37. Siegal J, Shandwick W (2020) Romark initiate new phase 3 clinical trial of NT-300 for the treatment of Covid-19. Romark Pharmaceuticals, United States.

38. Chaccour C, Hammann F, Ramón-García S, Rabinovich NR (2020) Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop MedHyg106:1156-1157.https://dx.doi.org/10.4269/ajtmh.20-0271

39. Rajter JC, Sherman M, Fatteh N, Vogel F, Sacks J, et al. (2020) Use of ivermectin is associated with lower mortality in hospitalized patients with COVID19. Medrxiv.https://doi.org/10.1101/2020.06.06.20124461

40. Bukreyeva N, Mantlo EK, Sattler RA, Huang C, Paessler S, et al. (2020) The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro.Biorxiv.https://doi.org/10.1101/2020.04.07.028589

41. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, et al. (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033-1034.https://dx.doi.org/10.1016/S0140-6736(20)30628-0

42. Xu X, Han M, Li T, Sun W, Wang D, et al. (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A117:10970-10975.https://doi.org/10.1073/pnas.2005615117

43. National Institute of Health (2020) Covid19 treatment guidelines interleukin-6 inhibitors. United States.

44. Genentech provides an update on the phase III COVACTA trial of actemra in hospitalized patients with severe COVID-19 associated pneumonia.

45. Demidowich AP, Davis AI, Dedhia N, Yanovski JA (2016) Colchicine to decrease NLRP3-activated

inflammation and improve obesity-related metabolic dysregulation. Med Hypotheses92:67-73.https://doi.org/10.1016/j.mehy.2016.04.039

46. Yousif NG (2014) Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK–PI 3 K/A kt pathway. Cell Biol Int 38: 85-91.https://doi.org/10.1002/cbin.10184

47. Simpson TF, Kovacs RJ, Stecker EC (2020) Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19. Am Coll Cardiol.

48. Important announcement of new SSC guidelines-COVID-19. ESICM, United States.

49. Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet395:473-475.https://doi.org/10.1016/S0140-6736(20)30317-2

50. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL,et al. (2020) Dexamethasone in hospitalized patients with Covid-19-preliminary report. New Engl J Med.https://doi.org/10.1056/NEJMoa2021436

51. Ramiro S, Mostard RL, Magro-Checa C, van Dongen CM, Dormans T, et al. (2020) Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis 79: 113-1151.http://dx.doi.org/10.1136/annrheumdis-2020-218479

52. Keller MJ, Kitsis EA, Arora S, Chen JT, Agarwal S, et al. (2020) Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med 15:489-493.https://doi.org/10.12788/jhm.3497

53. National Institute of Allery and Infectious Diseases (2020) NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins. United States.

54. Wang J, Wang BJ, Yang JC, Wang MY, Chen C, et al. (2020) Advances in the research of mechanism of pulmonary fibrosis induced by corona virus disease 2019 and the corresponding therapeutic measures. Zhonghua Shao Shang Za Zhi36:691-697.https://doi.org/10.3760/cma.j.cn501120-20200307-00132

55. Wynn TA (2011)Integrating mechanisms of pulmonary fibrosis. J Exp Med 208:1339-1350.https://doi.org/10.1084/jem.20110551

56. Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, et al. (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol RegulHomeost Agents34:1.

57. Jin J, Togo S, Kadoya K, Tulafu M, Namba Y, et al. (2019) Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1. Respir Res20:119.https://doi.org/10.1186/s12931-019-1093-z

58. Brian S. Singer; Stefan K Blinov (2014) The epidemiological characteristics of Ebola virus disease. Am JBioMed2:1095-1109.

59. Wong VWS, Dai D, Wu AKL, Sung JJK (2003) Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J9:199-201.

60. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, et al. (2015) The effectiveness of convalescent plasma and hyper immune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis211:80-90. https://doi.org/10.1093/infdis/jiu396

61. Duan K, Liu B, Li C, Zhang H, Yu T, et al. (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS117:9490-9496.https://doi.org/10.1073/pnas.2004168117

Chapter -7

Vaccines

Introduction

A vaccine is a biological preparation that improves immunity to a particular disease. It contains certain agents that not only resemble a disease-causing microorganism but it also stimulates the body's immune system to recognize the foreign agents. Vaccines are dead or inactivated organisms or purified products derived from them. There are several types of vaccines[1]:

1. Whole-Organism Vaccines
   - Killed
   - Attenuated
2. Purified Macromolecules as Vaccines
   - Toxoids
   - Capsular polysaccharides
   - Recombinant microbial antigens/Surface antigens
3. Recombinant vaccine
4. DNA vaccine
5. Multivalent Subunit Vaccines

Until now there are limited uses of the vaccine against coronavirus 19 and in the future or coming days or weeks we expect there are at least dozens of vaccine enter the testing and trial. A lot of strategies are used in the development of CoV vaccines; most of these target the surface-exposedspike (S) glycoprotein or S protein as the major inducer of neutralizing antibodies. and expression in virus-like particles (VLP), DNA, or viral vectors[2].

Recombinant Vaccine

Vaccines that are made from S-protein should induce antibodies that block both basic steps in pathogenesis like viral adhesion to the host receptors and viral genome releasing. It has been shown that the C-terminal domain of the S1 subunit of porcine Delta coronavirus constitutes the immune dominant region, and the immune response to this region shows the most potent neutralizing effect. The S protein can induce the immune response against SARS-CoV through eliciting neutralizing antibodies and T-cell responses [3].

Thus, full-length, or appropriate parts of the S glycoprotein are believed to be the most promising candidate CoV vaccine composition. It was also reported that neither the absence nor presence of the other structural proteins affects S protein immunogenicity or its binding to the ACE2 receptor that is a critical initial step for viruses to access into the host cell [4].

Due to the superior ability of RBD to induce neutralizing antibody, both recombinant proteins that contain RBD and the recombinant vectors that encode RBD can be used for developing the effective SARS-CoV vaccines.

The S protein molecule contains two subunits, S1 and S2:

S1 subunit: The S1 subunit has a receptor-binding domain (RBD) that interacts with angiotensin-converting enzyme 2 (ACE2) receptors found on the host cell surface [5].

S2 subunit: The S2 subunit mediates fusion between the virus and host cell membranes for releasing

viral RNA into the cytoplasm for replication.

Recently scientists used a recombinant technique to synthesis the COVID-19 vaccine, recombinant vaccine means inserts DNA specific sequence which encoding a specific protein that acts as an antigen to activate an immune response against the virus the recombinant protein used in COVID-19.

Recombinant adenovirus-based vaccine expressing MERS- CoV S protein: It is a type of vaccine when designed as an intranasal sprayer into BALB/c mice leading to induces systemic IgG, secretory IgA, and cell mediate immunity like lung- resident memory T-cell that leading to provide long-lasting neutralizing immunity to the protein of MERS protein (spike).

Microbes may use as vectors like Rabies virus (RV) & Gram-positive enhancer matrix (GEM) has been served to protect against MERS-CoV-spikes(S-protein). This type of vaccine can activate the cellular and humoral immune response.

The studies show that the structural protein of COVID19 similar to that protein found in the SARS & MERS virus that means they share the same epitopes which enhanced theT-cell epitopes, also COVID 19 shares a high similarity in gene with SARS-CoV-2 and this property may serve in vaccines developed for COVID-19[6].

Likewise, the close similarity of SARS-CoV-2 to the SARS-CoV suggests that the receptor of SARS-CoV-2 might be the same as that of the SARS-CoV receptor (ACE2).The immuno-informatics approach can be used for the identification of epitopes for inclusion in COVID-19 vaccine candidates.

Recently, immuno-informatics was used to identify significant cytotoxic T lymphocyte (CTL) and B-cell epitopes in SARS-CoV-2 S protein. The interactions between these epitopes and their corresponding MHC class I molecules were studied further by using molecular dynamics simulations and found that the CTL epitopes bind with MHC class I peptide-binding grooves via multiple contacts, thus indicating their potential for generating immune responses[7]. Such epitopes may possess the ideal characteristics to become part of COVID-19 vaccine candidates. The nucleocapsid (N) protein as well as the potential B cell epitopes of the E protein of MERS-CoV has been suggested as probable immune protective targets that induce both T-cell and neutralizing antibody responses.

Reverse genetic strategies have been successfully used in live-attenuated vaccines to inactivate the exonuclease effects of non-structural protein 14 (nsp14) or to delete the envelope protein in SARS.5 Avian infectious bronchitis virus (IBV) is a chicken CoV. It was suggested that avian live virus IBV vaccine (strain H) might be useful for SARS 33 given that protection provided by strain H is based on neutralizing antibody production as well as other immune responses. Hence, the avian IBV vaccine may be considered another option for COVID-19 after evaluating its safety in monkeys[8].

Scientists of Rocky Mountain Laboratories are collaborating with Oxford University to develop a chimpanzee, adenovirus-vectored COVID-19 vaccine candidate. The Coalition for Epidemic Preparedness Innovations (CEPI) recently announced the initiation of three programs aimed to develop COVID-19 vaccines by utilizing established vaccine platforms. 36 Among the three programs, two are continuations of previously initiated partnerships. CEPI collaborated with Inovio in 2018 to developing DNA vaccine candidates for MERS. The vaccine in development utilizes DNA Medicines'platform for delivering synthetic genes into cells for translation into antigenic proteins, which elicit T-cell and antibody responses. CEPI has collaborated with The University of Queensland in 2019 to develop the molecular clamp vaccine platform against multiple viral pathogens including MERS-CoV. The vaccine platform functions by synthesizing viral surface proteins that get attached to the host cells and clamp them into shape. This facilitates easier recognition of antigens by the immune system[9].

Other than these ongoing programs, CEPI has announced funding to Moderna for comparing mRNA therapeutics and vaccines. They will design and manufacture an mRNA vaccine in collaboration with the Vaccine Research. Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH).37 NIAID-VRC scientists are developing a vaccine

candidate expressing SARS-CoV-2 S protein in the mRNA vaccine platform technology. This vaccine is expected to undergo clinical testing in the coming months[10].

Passive Immunization

Direct administration of monoclonal antibodies (mAbs) may play an effective role in CoV control as an intervention in exposed individuals. It has been observed that patients recovering from SARS display potent neutralizing antibody responses. A clinical trial proposed the use of a set of mAbs that functionally target specific domains in MERS-CoV S protein. These mAbs bind to six specific epitope groups interacting with the receptor binding, membrane fusion, and sialic acid-binding sites, which represent the three important entry functions of MERS-CoV S protein.

Moreover, passive immunization with poorly and potently neutralizing antibodies induces substantial protection in mice subjected to lethal MERS-CoV challenge. Thus, the use of these antibodies may represent a novel approach to increase humoral protection against emerging CoVs by targeting various S protein epitopes and functions. The cross-neutralization capacity of SARS-CoV RBD-specific neutralizing mAbs greatly depends on the similarity between their RBDs. Therefore SARS-CoV RBD-specific antibodies can cross-neutralize SARS-like (SL) CoVs, i.e., bat-SL-CoV strain WIV1 RBD that had 8 amino acid differences to SARS-CoV, but not bat-SL-CoV strain SHC014 (24 amino acid differences) [11].

Such cross-neutralizing SARS-CoV RBD-specific mAbs can be evaluated for efficacy with SARS-CoV-2. This requires a comparative analysis of SARS-CoV-2 RBD with SARS-CoV so that suitable RBD-specific mAbs can be identified and evaluated in clinical trials. Regeneron is trying to identify mAbs specific and effective for COVID-19. Combination therapy with mAbs and the drug remdesivir could be an ideal therapeutic option for COVID-19.

Further evaluation is required before confirming the efficacy of such combination therapy. Technology is available for making fully human antibodies (such as human single-chain antibodies; Hu-scFvs) or humanized-nanobodies (single-domain antibodies, sdAb, VH/VHH) that can traverse across the membrane of the virus-infected cells (trans bodies) and bind to or interfere with biological activities of replicating virus proteins which consequently leads to inhibition of virus replication. Examples include trans bodies to influenza virus, hepatitis C virus, Ebola virus, and Dengue virus [10].

Thus, it is possible to generate trans bodies to CoV intracellular proteins such as the papain-like proteases cysteine-like protease, or other non-structural proteins that are pivotal for CoV replication and transcription for safe, non-immunogenic, broadly effective passive immunization of CoV- exposed subjects and treatment of infected patients. Animal models for vaccine evaluation Suitable animal models for evaluating vaccines for SARS- and MERS-CoV are lacking or highly limited, making the process of vaccine development highly challenging.

Development of an efficient animal model that mimics the clinical disease can inform on pathogenesis as well as develop vaccines and therapeutics against these CoVs. Several animal models have been evaluated for SARS- and MERS CoVs including mouse, guinea pigs, hamsters, ferrets, rabbits, rhesus macaques, marmosets, and cats.

An early effort was directed in developing animal models for SARS-CoV, but the specificity of the virus to ACE2 (receptor of SARS-CoV) was a major hindrance to such efforts. Later, a SARS-CoV transgenic mouse model was developed by introducing the hACE2 gene into the mouse genome [12].

The first animal model used for developing a MERS-CoV vaccine was rhesus macaques. Infected animals showed clinical symptoms such as increased body temperature, piloerection, cough, hunched posture, and reduced food intake.

Another frequently used animal model for MERS-CoV is the common marmoset, wherein the virus caused lethal pneumonia. Humoral and cell-mediated immunity could be detected in both rhesus macaques and common marmoset following MERS-CoV immunization. Roberts et al. established golden

Syrian hamsters (strain LVG) as a model to assess vaccine protection to different SARS-CoV strains. These hamsters are a potential model for studying CoV pathology and pathogenesis and vaccine efficacy. The attenuated NSP16 CoV vaccine was studied in mice. Attempts to develop animal models for MERS-CoV such as mice, hamsters, and ferrets face limitations due to the inability of MERS-CoV to replicate in the respiratory tracts of these species. Small animals (mice or hamsters) resisting natural infection with MERS-CoVs (which are susceptible to SARS-CoV) have been genetically modified to a more humanized structure, e.g., hDPP4 human, hDPP4-transduced, and DPP4-Tg mice (transgenic for expressing hDPP4), and ascertained for susceptibility to MERS-CoV infection [13].

Alteration in the mouse genome using the CRISPR-Cas9 gene-editing tool could make the animals susceptible to CoV infection and virus replication.56 Genetic engineering was used in the generation of 288-330 MERS-CoV mouse model, which is being used for the evaluation of novel MERS-CoV vaccines and drugs. Compared to the large animal models, small animals such as mice and rabbits are preferred due to lower cost, ease of manipulation, and readily available efficacy methods.

Further studies are needed to recognize suitable models for emerging SARS-CoV-2 by identifying receptor affinity of SARS-CoV-2 and studying disease manifestations, pathologies/viral pathogenesis associated with experimental inoculation of the virus in mice, rats, and other models, as well as examining virus-specific immune responses and protection [14].

This would facilitate preclinical evaluations of candidate COVID-19 vaccines and drugs. Cell culture systems Several permissive cell lines to hCoVs including monkey epithelial cell lines (LLC-MK2 and Vero-B4) have been used in neutralization assays for assessing neutralization titers of antibody preparations. Goat lung cells, alpaca kidney cells, and dromedary umbilical cord cells are permissive for MERS-CoV.

SARS-CoV S protein has been found to mediate entry into hepatoma cell lines, targeted by neutralizing antibodies in virus-infected patients. Advanced ex–vivo 3D tracheobronchial tissue (mimicking epithelium of conductive airway) has been used for human CoVs[15].

Moreover, VLPs displaying SARS-CoV S protein were found competent for entry to permissive cells or transfected cells that overexpress virus receptors. SARS-CoV-2 isolation has been attempted in Vero and the Huh-7 cells (human liver cancer cells). Pseudo typed virions/VLPs encoding reporter systems such as GFP or luciferase can be used for quantification and evaluation of the effectiveness of mAbs and drugs in inhibiting the cellular entry of CoVs.

Assays using pseudotyped virions/VLPs can be performed in a BSL-2 facility since these do not use infectious virus. A safety concern for passive immunization with antibodies is a possible antibody-dependent enhancement (ADE) of virus replication. Antibodies with modified Fc fragments or without Fc fragment, e.g., human single-chain antibodies (scFv), Fab, or F(ab′)2 are safe alternatives. Several mAbs (fully human or humanized) that target both the S1-RBD and non-RBD, as well as the S2 domain of CoVs, have been generated and tested in cell cultures for virus-neutralizing capability as well as in animal models for prophylactic and post-exposure efficacies [1,3].

These antibodies could be useful tools also in the development of vaccines, therapeutic drugs, and antiviral inhibitors. Data from animal CoV vaccination suggest that systemic humoral or cell-mediated immune responses induced by parenteral administration may not be adequate to prevent respiratory tract infection [5].

Because respiratory mucosa is the initial site in CoV infection and transmission, mucosal immunization, such as using the intranasal vaccine, 67 could be an effective strategy for prophylaxis by induction of mucosal and systemic immune responses. The molecular mechanisms of mucosal and systemic immunological factors are different, such that it is difficult to predict the surrogate marker for CoV efficacy. The best surrogate assays for protection as well as herd immunity toward different CoV infections warrant detailed investigations [7].

References

1. Pulendran B (2020) Systems vaccinology: probing humanity's diverse immune systems with vaccines. Proc Natl Acad Sci USA111:12300-12306.https://doi.org/10.1073/pnas.1400476111

2. Singer BS, Blinov SK (2014) The epidemiological characteristics of Ebola virus disease. Am J BioMed 2: 1095-1109.

3. Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, et al. (2020) Potential rapid diagnostics, vaccine, and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med9:623.https://doi.org/10.3390/jcm9030623

4. Zhang L, Liu Y (2020) Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 92:479-490.https://doi.org/10.1002/jmv.25707

5. Keller SA, Bolan GB (2016) Herpes simplex in leukemic child: an unusual presentation. AmJ BioMed4:534-542.

6. Kumar D, Malviya R, Sharma PK (2020) Coronavirus: a review of COVID-19. Eurasian J Med Oncol4:8-25. https://dx.doi.org/10.14744/ejmo.2020.51418

7. Eyal N, Lipsitch M, Smith PG (2020) Human challenge studies to accelerate coronavirus vaccine licensure. J Infect Dis221:1752-1756.https://doi.org/10.1093/infdis/jiaa152

8. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, et al. (2020) The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg78:185.https://dx.doi.org/10.1016/j.ijsu.2020.04.018

9. World Health Organization (2020) WHO statement regarding cluster of pneumonia cases in Wuhan, China. Switzerland.

10. Zhu N, Zhang D, Wang W, Li X, Yang B, et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med 382:727-733.https://doi.org/10.1056/NEJMoa2001017

11. Mailles A, Blanckaert K, Chaud P, Van der Werf S, Lina B, et al. (2013) First cases of Middle East respiratory syndrome Coronavirus (MERS-CoV) infections in France, investigations, and implications for the prevention of human-to-human transmission. Eurosurveill18:20502.https://doi.org/10.2807/ese.18.24.20502-en

12. Huang C, Wang Y, Li X, Ren L, Zhao J, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506.https://doi.org/10.1016/S0140-6736(20)30183-5

13. Chan JF, Yuan S, Kok KH, To KK, Chu H, et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395: 514-523.https://doi.org/10.1016/S0140-6736(20)30154-9

14. European Centre for Disease Prevention and Control (ECDC) (2020) Case definition and European surveillance for human infection with the novel coronavirus (2019-nCoV). Sweden.

15. European Centre for Disease Prevention and Control (ECDC) (2019) Health emergency preparedness for imported cases of high-consequence infectious diseases 2019. Sweden.



Scholars

LITERATURE

ISBN: 978-0-578-77148-9